SK3812002A3 - Pyrazolopyrimidines as therapeutic agents - Google Patents

Info

Publication number

SK3812002A3

SK3812002A3 SK381-2002A SK3812002A SK3812002A3 SK 3812002 A3 SK3812002 A3 SK 3812002A3 SK 3812002 A SK3812002 A SK 3812002A SK 3812002 A3 SK3812002 A3 SK 3812002A3

Authority

SK

Slovakia

Prior art keywords

substituted

unsubstituted

group

alkyl

hydrogen

Prior art date

1999-09-17

Links

• Espacenet
• Global Dossier
• Discuss

• 239000003814 drug Substances 0.000 title claims description 24
• 229940124597 therapeutic agent Drugs 0.000 title claims description 9
• APXRHPDHORGIEB-UHFFFAOYSA-N 1H-pyrazolo[4,3-d]pyrimidine Chemical class N1=CN=C2C=NNC2=C1 APXRHPDHORGIEB-UHFFFAOYSA-N 0.000 title 1
• 150000001875 compounds Chemical class 0.000 claims abstract description 365
• 150000003839 salts Chemical class 0.000 claims abstract description 48
• 239000000651 prodrug Substances 0.000 claims abstract description 19
• 229940002612 prodrug Drugs 0.000 claims abstract description 19
• -1 2,3-dihydrobenzofuranyl Chemical group 0.000 claims description 193
• 125000000217 alkyl group Chemical group 0.000 claims description 171
• 229910052739 hydrogen Inorganic materials 0.000 claims description 158
• 239000001257 hydrogen Substances 0.000 claims description 149
• 125000003118 aryl group Chemical group 0.000 claims description 102
• 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 84
• 239000000203 mixture Substances 0.000 claims description 81
• 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims description 64
• 229910052757 nitrogen Inorganic materials 0.000 claims description 63
• 125000001424 substituent group Chemical group 0.000 claims description 63
• 230000000694 effects Effects 0.000 claims description 59
• UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 57
• 125000000623 heterocyclic group Chemical group 0.000 claims description 57
• 201000010099 disease Diseases 0.000 claims description 56
• 125000004433 nitrogen atom Chemical group N* 0.000 claims description 52
• 125000004435 hydrogen atom Chemical group [H]* 0.000 claims description 51
• 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 51
• 125000001072 heteroaryl group Chemical group 0.000 claims description 50
• 125000003710 aryl alkyl group Chemical group 0.000 claims description 49
• 102100033177 Vascular endothelial growth factor receptor 2 Human genes 0.000 claims description 45
• 102000001253 Protein Kinase Human genes 0.000 claims description 44
• 108060006633 protein kinase Proteins 0.000 claims description 44
• 125000000592 heterocycloalkyl group Chemical group 0.000 claims description 41
• 102000004022 Protein-Tyrosine Kinases Human genes 0.000 claims description 39
• 108090000412 Protein-Tyrosine Kinases Proteins 0.000 claims description 39
• 101100481410 Mus musculus Tek gene Proteins 0.000 claims description 31
• 206010028980 Neoplasm Diseases 0.000 claims description 31
• IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 30
• 101100481408 Danio rerio tie2 gene Proteins 0.000 claims description 29
• 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 28
• 125000004183 alkoxy alkyl group Chemical group 0.000 claims description 26
• 125000004093 cyano group Chemical group *C#N 0.000 claims description 26
• 229910052731 fluorine Inorganic materials 0.000 claims description 25
• 125000003545 alkoxy group Chemical group 0.000 claims description 23
• 230000033115 angiogenesis Effects 0.000 claims description 23
• 208000035475 disorder Diseases 0.000 claims description 23
• 125000004453 alkoxycarbonyl group Chemical group 0.000 claims description 22
• 125000004448 alkyl carbonyl group Chemical group 0.000 claims description 22
• 229910052717 sulfur Inorganic materials 0.000 claims description 21
• 229910004013 NO 2 Inorganic materials 0.000 claims description 20
• 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 20
• 125000002768 hydroxyalkyl group Chemical group 0.000 claims description 20
• 201000011510 cancer Diseases 0.000 claims description 19
• 230000002401 inhibitory effect Effects 0.000 claims description 19
• 239000002207 metabolite Substances 0.000 claims description 19
• 229910052760 oxygen Inorganic materials 0.000 claims description 19
• 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims description 18
• 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 18
• 238000002360 preparation method Methods 0.000 claims description 18
• 125000004430 oxygen atom Chemical group O* 0.000 claims description 17
• 229910052736 halogen Inorganic materials 0.000 claims description 16
• 150000002367 halogens Chemical class 0.000 claims description 16
• 125000002618 bicyclic heterocycle group Chemical group 0.000 claims description 15
• 229910052801 chlorine Inorganic materials 0.000 claims description 15
• 125000004076 pyridyl group Chemical group 0.000 claims description 15
• 230000004913 activation Effects 0.000 claims description 14
• 150000001413 amino acids Chemical class 0.000 claims description 14
• 229920006395 saturated elastomer Polymers 0.000 claims description 14
• 125000000547 substituted alkyl group Chemical group 0.000 claims description 14
• 239000003102 growth factor Substances 0.000 claims description 13
• 101001059454 Homo sapiens Serine/threonine-protein kinase MARK2 Proteins 0.000 claims description 12
• 102100028904 Serine/threonine-protein kinase MARK2 Human genes 0.000 claims description 12
• 229910052794 bromium Inorganic materials 0.000 claims description 12
• 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 12
• 125000002541 furyl group Chemical group 0.000 claims description 12
• 108010053100 Vascular Endothelial Growth Factor Receptor-3 Proteins 0.000 claims description 11
• 208000028867 ischemia Diseases 0.000 claims description 11
• 125000002971 oxazolyl group Chemical group 0.000 claims description 11
• 230000001225 therapeutic effect Effects 0.000 claims description 11
• HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 10
• 125000000499 benzofuranyl group Chemical group O1C(=CC2=C1C=CC=C2)* 0.000 claims description 10
• 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 10
• 125000004070 6 membered heterocyclic group Chemical group 0.000 claims description 9
• 206010016654 Fibrosis Diseases 0.000 claims description 9
• 230000006044 T cell activation Effects 0.000 claims description 9
• 108010073923 Vascular Endothelial Growth Factor C Proteins 0.000 claims description 9
• 125000001164 benzothiazolyl group Chemical group S1C(=NC2=C1C=CC=C2)* 0.000 claims description 9
• 125000004541 benzoxazolyl group Chemical group O1C(=NC2=C1C=CC=C2)* 0.000 claims description 9
• PXBRQCKWGAHEHS-UHFFFAOYSA-N dichlorodifluoromethane Chemical compound FC(F)(Cl)Cl PXBRQCKWGAHEHS-UHFFFAOYSA-N 0.000 claims description 9
• 208000015181 infectious disease Diseases 0.000 claims description 9
• 102100040681 Platelet-derived growth factor C Human genes 0.000 claims description 8
• 201000004681 Psoriasis Diseases 0.000 claims description 8
• YTPLMLYBLZKORZ-UHFFFAOYSA-N Thiophene Chemical compound C=1C=CSC=1 YTPLMLYBLZKORZ-UHFFFAOYSA-N 0.000 claims description 8
• 206010052779 Transplant rejections Diseases 0.000 claims description 8
• 208000025865 Ulcer Diseases 0.000 claims description 8
• 125000004103 aminoalkyl group Chemical group 0.000 claims description 8
• 125000000753 cycloalkyl group Chemical group 0.000 claims description 8
• 230000003463 hyperproliferative effect Effects 0.000 claims description 8
• 125000001041 indolyl group Chemical group 0.000 claims description 8
• 108010017992 platelet-derived growth factor C Proteins 0.000 claims description 8
• 230000001023 pro-angiogenic effect Effects 0.000 claims description 8
• CYRMSUTZVYGINF-UHFFFAOYSA-N trichlorofluoromethane Chemical compound FC(Cl)(Cl)Cl CYRMSUTZVYGINF-UHFFFAOYSA-N 0.000 claims description 8
• 231100000397 ulcer Toxicity 0.000 claims description 8
• XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 7
• 206010035226 Plasma cell myeloma Diseases 0.000 claims description 7
• 108010073919 Vascular Endothelial Growth Factor D Proteins 0.000 claims description 7
• 102000016663 Vascular Endothelial Growth Factor Receptor-3 Human genes 0.000 claims description 7
• 125000003785 benzimidazolyl group Chemical group N1=C(NC2=C1C=CC=C2)* 0.000 claims description 7
• 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 7
• 230000001684 chronic effect Effects 0.000 claims description 7
• 208000014674 injury Diseases 0.000 claims description 7
• 125000000842 isoxazolyl group Chemical group 0.000 claims description 7
• 201000000050 myeloid neoplasm Diseases 0.000 claims description 7
• 206010012689 Diabetic retinopathy Diseases 0.000 claims description 6
• 108090000386 Fibroblast Growth Factor 1 Proteins 0.000 claims description 6
• 206010018364 Glomerulonephritis Diseases 0.000 claims description 6
• 206010021143 Hypoxia Diseases 0.000 claims description 6
• 208000022559 Inflammatory bowel disease Diseases 0.000 claims description 6
• 125000005223 heteroarylcarbonyl group Chemical group 0.000 claims description 6
• 230000007954 hypoxia Effects 0.000 claims description 6
• 229910052740 iodine Inorganic materials 0.000 claims description 6
• 210000001616 monocyte Anatomy 0.000 claims description 6
• 125000000951 phenoxy group Chemical group [H]C1=C([H])C([H])=C(O*)C([H])=C1[H] 0.000 claims description 6
• 125000003170 phenylsulfonyl group Chemical group C1(=CC=CC=C1)S(=O)(=O)* 0.000 claims description 6
• 208000037803 restenosis Diseases 0.000 claims description 6
• 206010039073 rheumatoid arthritis Diseases 0.000 claims description 6
• 208000024891 symptom Diseases 0.000 claims description 6
• 125000003831 tetrazolyl group Chemical group 0.000 claims description 6
• 125000001544 thienyl group Chemical group 0.000 claims description 6
• 102100022014 Angiopoietin-1 receptor Human genes 0.000 claims description 5
• 201000001320 Atherosclerosis Diseases 0.000 claims description 5
• 206010010741 Conjunctivitis Diseases 0.000 claims description 5
• 208000011231 Crohn disease Diseases 0.000 claims description 5
• 208000010412 Glaucoma Diseases 0.000 claims description 5
• 101000753291 Homo sapiens Angiopoietin-1 receptor Proteins 0.000 claims description 5
• 208000001344 Macular Edema Diseases 0.000 claims description 5
• 206010025415 Macular oedema Diseases 0.000 claims description 5
• 241000700639 Parapoxvirus Species 0.000 claims description 5
• 241000700605 Viruses Species 0.000 claims description 5
• 229910002091 carbon monoxide Inorganic materials 0.000 claims description 5
• 125000004181 carboxyalkyl group Chemical group 0.000 claims description 5
• 206010012601 diabetes mellitus Diseases 0.000 claims description 5
• 230000004761 fibrosis Effects 0.000 claims description 5
• 201000010230 macular retinal edema Diseases 0.000 claims description 5
• 125000001624 naphthyl group Chemical group 0.000 claims description 5
• 208000011580 syndromic disease Diseases 0.000 claims description 5
• 230000009885 systemic effect Effects 0.000 claims description 5
• 208000024172 Cardiovascular disease Diseases 0.000 claims description 4
• 201000009273 Endometriosis Diseases 0.000 claims description 4
• 206010017533 Fungal infection Diseases 0.000 claims description 4
• 206010025323 Lymphomas Diseases 0.000 claims description 4
• 206010027295 Menometrorrhagia Diseases 0.000 claims description 4
• 208000031888 Mycoses Diseases 0.000 claims description 4
• 208000010191 Osteitis Deformans Diseases 0.000 claims description 4
• 206010033266 Ovarian Hyperstimulation Syndrome Diseases 0.000 claims description 4
• 208000027868 Paget disease Diseases 0.000 claims description 4
• 208000006011 Stroke Diseases 0.000 claims description 4
• 125000005078 alkoxycarbonylalkyl group Chemical group 0.000 claims description 4
• 125000004390 alkyl sulfonyl group Chemical group 0.000 claims description 4
• 125000001589 carboacyl group Chemical group 0.000 claims description 4
• 125000002837 carbocyclic group Chemical group 0.000 claims description 4
• 125000004432 carbon atom Chemical group C* 0.000 claims description 4
• 230000006020 chronic inflammation Effects 0.000 claims description 4
• 230000007882 cirrhosis Effects 0.000 claims description 4
• 208000019425 cirrhosis of liver Diseases 0.000 claims description 4
• 125000004966 cyanoalkyl group Chemical group 0.000 claims description 4
• 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 4
• 125000002883 imidazolyl group Chemical group 0.000 claims description 4
• 230000028709 inflammatory response Effects 0.000 claims description 4
• 208000032839 leukemia Diseases 0.000 claims description 4
• 208000002780 macular degeneration Diseases 0.000 claims description 4
• 208000027202 mammary Paget disease Diseases 0.000 claims description 4
• 201000006417 multiple sclerosis Diseases 0.000 claims description 4
• 208000010125 myocardial infarction Diseases 0.000 claims description 4
• 229910052698 phosphorus Inorganic materials 0.000 claims description 4
• 125000003386 piperidinyl group Chemical group 0.000 claims description 4
• 208000030761 polycystic kidney disease Diseases 0.000 claims description 4
• 201000011461 pre-eclampsia Diseases 0.000 claims description 4
• 125000000168 pyrrolyl group Chemical group 0.000 claims description 4
• 201000000306 sarcoidosis Diseases 0.000 claims description 4
• 125000003718 tetrahydrofuranyl group Chemical group 0.000 claims description 4
• 125000001712 tetrahydronaphthyl group Chemical group C1(CCCC2=CC=CC=C12)* 0.000 claims description 4
• 125000001412 tetrahydropyranyl group Chemical group 0.000 claims description 4
• 125000000335 thiazolyl group Chemical group 0.000 claims description 4
• 125000005309 thioalkoxy group Chemical group 0.000 claims description 4
• 229930192474 thiophene Natural products 0.000 claims description 4
• 206010043778 thyroiditis Diseases 0.000 claims description 4
• 208000035143 Bacterial infection Diseases 0.000 claims description 3
• 101100481403 Bos taurus TIE1 gene Proteins 0.000 claims description 3
• 206010009900 Colitis ulcerative Diseases 0.000 claims description 3
• 206010054044 Diabetic microangiopathy Diseases 0.000 claims description 3
• 108090000379 Fibroblast growth factor 2 Proteins 0.000 claims description 3
• 102100023593 Fibroblast growth factor receptor 1 Human genes 0.000 claims description 3
• 101710182386 Fibroblast growth factor receptor 1 Proteins 0.000 claims description 3
• 208000002250 Hematologic Neoplasms Diseases 0.000 claims description 3
• 102100021866 Hepatocyte growth factor Human genes 0.000 claims description 3
• 208000009889 Herpes Simplex Diseases 0.000 claims description 3
• 208000007514 Herpes zoster Diseases 0.000 claims description 3
• 208000007766 Kaposi sarcoma Diseases 0.000 claims description 3
• 208000024599 Mooren ulcer Diseases 0.000 claims description 3
• 206010029260 Neuroblastoma Diseases 0.000 claims description 3
• 206010053869 POEMS syndrome Diseases 0.000 claims description 3
• 206010034277 Pemphigoid Diseases 0.000 claims description 3
• 206010063837 Reperfusion injury Diseases 0.000 claims description 3
• 206010038848 Retinal detachment Diseases 0.000 claims description 3
• 201000000582 Retinoblastoma Diseases 0.000 claims description 3
• 206010038923 Retinopathy Diseases 0.000 claims description 3
• 206010039491 Sarcoma Diseases 0.000 claims description 3
• 206010039705 Scleritis Diseases 0.000 claims description 3
• 206010040047 Sepsis Diseases 0.000 claims description 3
• 201000005485 Toxoplasmosis Diseases 0.000 claims description 3
• 206010067584 Type 1 diabetes mellitus Diseases 0.000 claims description 3
• 201000006704 Ulcerative Colitis Diseases 0.000 claims description 3
• 206010064996 Ulcerative keratitis Diseases 0.000 claims description 3
• 206010046851 Uveitis Diseases 0.000 claims description 3
• 108010073925 Vascular Endothelial Growth Factor B Proteins 0.000 claims description 3
• 108010019530 Vascular Endothelial Growth Factors Proteins 0.000 claims description 3
• 102000005789 Vascular Endothelial Growth Factors Human genes 0.000 claims description 3
• 102100038217 Vascular endothelial growth factor B Human genes 0.000 claims description 3
• 206010053648 Vascular occlusion Diseases 0.000 claims description 3
• 206010047663 Vitritis Diseases 0.000 claims description 3
• 208000027418 Wounds and injury Diseases 0.000 claims description 3
• 150000001412 amines Chemical class 0.000 claims description 3
• 208000007502 anemia Diseases 0.000 claims description 3
• 125000005110 aryl thio group Chemical group 0.000 claims description 3
• 230000001580 bacterial effect Effects 0.000 claims description 3
• 208000022362 bacterial infectious disease Diseases 0.000 claims description 3
• 230000009286 beneficial effect Effects 0.000 claims description 3
• 125000005605 benzo group Chemical group 0.000 claims description 3
• 208000037976 chronic inflammation Diseases 0.000 claims description 3
• 230000006378 damage Effects 0.000 claims description 3
• 201000009101 diabetic angiopathy Diseases 0.000 claims description 3
• 208000030533 eye disease Diseases 0.000 claims description 3
• 230000009033 hematopoietic malignancy Effects 0.000 claims description 3
• 125000005368 heteroarylthio group Chemical group 0.000 claims description 3
• 210000003630 histaminocyte Anatomy 0.000 claims description 3
• 208000013653 hyalitis Diseases 0.000 claims description 3
• 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims description 3
• 238000013532 laser treatment Methods 0.000 claims description 3
• 206010025135 lupus erythematosus Diseases 0.000 claims description 3
• 208000001491 myopia Diseases 0.000 claims description 3
• 230000004379 myopia Effects 0.000 claims description 3
• 230000000414 obstructive effect Effects 0.000 claims description 3
• 230000003287 optical effect Effects 0.000 claims description 3
• 201000008482 osteoarthritis Diseases 0.000 claims description 3
• 125000001715 oxadiazolyl group Chemical group 0.000 claims description 3
• 125000004043 oxo group Chemical group O=* 0.000 claims description 3
• 230000004264 retinal detachment Effects 0.000 claims description 3
• 201000009410 rhabdomyosarcoma Diseases 0.000 claims description 3
• 208000007056 sickle cell anemia Diseases 0.000 claims description 3
• 201000004595 synovitis Diseases 0.000 claims description 3
• 125000001113 thiadiazolyl group Chemical group 0.000 claims description 3
• 208000021331 vascular occlusion disease Diseases 0.000 claims description 3
• 230000004862 vasculogenesis Effects 0.000 claims description 3
• 208000006542 von Hippel-Lindau disease Diseases 0.000 claims description 3
• YBYIRNPNPLQARY-UHFFFAOYSA-N 1H-indene Natural products C1=CC=C2CC=CC2=C1 YBYIRNPNPLQARY-UHFFFAOYSA-N 0.000 claims description 2
• 230000003844 B-cell-activation Effects 0.000 claims description 2
• 102000003971 Fibroblast Growth Factor 1 Human genes 0.000 claims description 2
• 102000003974 Fibroblast growth factor 2 Human genes 0.000 claims description 2
• 201000008808 Fibrosarcoma Diseases 0.000 claims description 2
• 206010017711 Gangrene Diseases 0.000 claims description 2
• 208000017604 Hodgkin disease Diseases 0.000 claims description 2
• 208000010747 Hodgkins lymphoma Diseases 0.000 claims description 2
• 101000898034 Homo sapiens Hepatocyte growth factor Proteins 0.000 claims description 2
• 101001076408 Homo sapiens Interleukin-6 Proteins 0.000 claims description 2
• 101000868152 Homo sapiens Son of sevenless homolog 1 Proteins 0.000 claims description 2
• 208000016604 Lyme disease Diseases 0.000 claims description 2
• 206010028851 Necrosis Diseases 0.000 claims description 2
• OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 2
• 102000001393 Platelet-Derived Growth Factor alpha Receptor Human genes 0.000 claims description 2
• 108010068588 Platelet-Derived Growth Factor alpha Receptor Proteins 0.000 claims description 2
• 101000852966 Rattus norvegicus Interleukin-1 receptor-like 1 Proteins 0.000 claims description 2
• 208000017442 Retinal disease Diseases 0.000 claims description 2
• 125000003342 alkenyl group Chemical group 0.000 claims description 2
• 125000006356 alkylene carbonyl group Chemical group 0.000 claims description 2
• 125000002947 alkylene group Chemical group 0.000 claims description 2
• 125000000304 alkynyl group Chemical group 0.000 claims description 2
• 125000003277 amino group Chemical group 0.000 claims description 2
• 125000005129 aryl carbonyl group Chemical group 0.000 claims description 2
• 125000004196 benzothienyl group Chemical group S1C(=CC2=C1C=CC=C2)* 0.000 claims description 2
• 125000001951 carbamoylamino group Chemical group C(N)(=O)N* 0.000 claims description 2
• 125000005518 carboxamido group Chemical group 0.000 claims description 2
• 125000001995 cyclobutyl group Chemical group [H]C1([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 2
• 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 2
• 230000035558 fertility Effects 0.000 claims description 2
• 125000001153 fluoro group Chemical group F* 0.000 claims description 2
• 208000005017 glioblastoma Diseases 0.000 claims description 2
• 125000005224 heteroarylcarbonylamino group Chemical group 0.000 claims description 2
• 125000006517 heterocyclyl carbonyl group Chemical group 0.000 claims description 2
• 125000005181 hydroxyalkylaminoalkyl group Chemical group 0.000 claims description 2
• 125000004029 hydroxymethyl group Chemical group [H]OC([H])([H])* 0.000 claims description 2
• 125000003454 indenyl group Chemical group C1(C=CC2=CC=CC=C12)* 0.000 claims description 2
• 125000003387 indolinyl group Chemical group N1(CCC2=CC=CC=C12)* 0.000 claims description 2
• 125000001786 isothiazolyl group Chemical group 0.000 claims description 2
• 201000001441 melanoma Diseases 0.000 claims description 2
• 125000001160 methoxycarbonyl group Chemical group [H]C([H])([H])OC(*)=O 0.000 claims description 2
• 125000004573 morpholin-4-yl group Chemical group N1(CCOCC1)* 0.000 claims description 2
• 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
• 230000017074 necrotic cell death Effects 0.000 claims description 2
• 208000008798 osteoma Diseases 0.000 claims description 2
• 125000004437 phosphorous atom Chemical group 0.000 claims description 2
• 239000011574 phosphorus Substances 0.000 claims description 2
• 125000003226 pyrazolyl group Chemical group 0.000 claims description 2
• 208000001608 teratocarcinoma Diseases 0.000 claims description 2
• 208000035408 type 1 diabetes mellitus 1 Diseases 0.000 claims description 2
• 150000002431 hydrogen Chemical class 0.000 claims 41
• 208000029483 Acquired immunodeficiency Diseases 0.000 claims 1
• 102000009520 Vascular Endothelial Growth Factor C Human genes 0.000 claims 1
• 102000009519 Vascular Endothelial Growth Factor D Human genes 0.000 claims 1
• 229910052799 carbon Inorganic materials 0.000 claims 1
• CMWTZPSULFXXJA-VIFPVBQESA-N naproxen Chemical group C1=C([C@H](C)C(O)=O)C=CC2=CC(OC)=CC=C21 CMWTZPSULFXXJA-VIFPVBQESA-N 0.000 claims 1
• QJGQUHMNIGDVPM-UHFFFAOYSA-N nitrogen group Chemical group [N] QJGQUHMNIGDVPM-UHFFFAOYSA-N 0.000 claims 1
• 230000002685 pulmonary effect Effects 0.000 claims 1
• 229940124530 sulfonamide Drugs 0.000 claims 1
• 150000003456 sulfonamides Chemical class 0.000 claims 1
• 229940045988 antineoplastic drug protein kinase inhibitors Drugs 0.000 abstract 1
• 239000003909 protein kinase inhibitor Substances 0.000 abstract 1
• XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 150
• YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 97
• 210000004027 cell Anatomy 0.000 description 77
• IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 74
• OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 66
• 239000000543 intermediate Substances 0.000 description 64
• 239000007787 solid Substances 0.000 description 63
• 108010053099 Vascular Endothelial Growth Factor Receptor-2 Proteins 0.000 description 55
• 235000019439 ethyl acetate Nutrition 0.000 description 55
• 238000000034 method Methods 0.000 description 53
• 239000000243 solution Substances 0.000 description 51
• 235000002639 sodium chloride Nutrition 0.000 description 48
• XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 46
• LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 39
• QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 32
• CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 30
• WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 28
• 102000005962 receptors Human genes 0.000 description 28
• 239000003446 ligand Substances 0.000 description 27
• 108020003175 receptors Proteins 0.000 description 27
• 206010030113 Oedema Diseases 0.000 description 26
• 238000006243 chemical reaction Methods 0.000 description 26
• 230000005764 inhibitory process Effects 0.000 description 26
• 230000002792 vascular Effects 0.000 description 26
• IMNFDUFMRHMDMM-UHFFFAOYSA-N N-Heptane Chemical compound CCCCCCC IMNFDUFMRHMDMM-UHFFFAOYSA-N 0.000 description 25
• 108091000080 Phosphotransferase Proteins 0.000 description 24
• HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 24
• 102000020233 phosphotransferase Human genes 0.000 description 24
• 108090000623 proteins and genes Proteins 0.000 description 24
• 108091008598 receptor tyrosine kinases Proteins 0.000 description 24
• 239000011541 reaction mixture Substances 0.000 description 23
• 102000027426 receptor tyrosine kinases Human genes 0.000 description 23
• 102000004190 Enzymes Human genes 0.000 description 22
• 108090000790 Enzymes Proteins 0.000 description 22
• 241000282414 Homo sapiens Species 0.000 description 22
• 230000015572 biosynthetic process Effects 0.000 description 22
• 229940088598 enzyme Drugs 0.000 description 22
• 239000003112 inhibitor Substances 0.000 description 21
• 230000001404 mediated effect Effects 0.000 description 21
• OYRRZWATULMEPF-UHFFFAOYSA-N pyrimidin-4-amine Chemical compound NC1=CC=NC=N1 OYRRZWATULMEPF-UHFFFAOYSA-N 0.000 description 21
• 238000011282 treatment Methods 0.000 description 21
• 101100372762 Rattus norvegicus Flt1 gene Proteins 0.000 description 20
• 102000004169 proteins and genes Human genes 0.000 description 20
• 101100381481 Caenorhabditis elegans baz-2 gene Proteins 0.000 description 19
• 235000018102 proteins Nutrition 0.000 description 19
• RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 18
• 239000010410 layer Substances 0.000 description 18
• UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 17
• FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 17
• 230000002829 reductive effect Effects 0.000 description 17
• 239000000758 substrate Substances 0.000 description 17
• 241000699670 Mus sp. Species 0.000 description 16
• 101150001535 SRC gene Proteins 0.000 description 16
• 230000008569 process Effects 0.000 description 16
• 238000003818 flash chromatography Methods 0.000 description 15
• 239000012299 nitrogen atmosphere Substances 0.000 description 15
• 239000012044 organic layer Substances 0.000 description 15
• 230000004044 response Effects 0.000 description 15
• 239000002904 solvent Substances 0.000 description 15
• 230000002491 angiogenic effect Effects 0.000 description 14
• 239000000725 suspension Substances 0.000 description 14
• 108091007914 CDKs Proteins 0.000 description 13
• 102000016549 Vascular Endothelial Growth Factor Receptor-2 Human genes 0.000 description 13
• 238000001914 filtration Methods 0.000 description 13
• 230000014509 gene expression Effects 0.000 description 13
• 239000012071 phase Substances 0.000 description 13
• 238000006366 phosphorylation reaction Methods 0.000 description 13
• VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 description 12
• ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 description 12
• 206010029113 Neovascularisation Diseases 0.000 description 12
• YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 description 12
• 238000003556 assay Methods 0.000 description 12
• 239000000872 buffer Substances 0.000 description 12
• 210000002889 endothelial cell Anatomy 0.000 description 12
• 238000009472 formulation Methods 0.000 description 12
• 239000003921 oil Substances 0.000 description 12
• 235000019198 oils Nutrition 0.000 description 12
• 230000026731 phosphorylation Effects 0.000 description 12
• 239000012321 sodium triacetoxyborohydride Substances 0.000 description 12
• 238000003756 stirring Methods 0.000 description 12
• 101150012716 CDK1 gene Proteins 0.000 description 11
• 238000002965 ELISA Methods 0.000 description 11
• 241001465754 Metazoa Species 0.000 description 11
• 229960000583 acetic acid Drugs 0.000 description 11
• 238000001727 in vivo Methods 0.000 description 11
• 239000011734 sodium Substances 0.000 description 11
• KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 description 10
• NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 10
• 235000001014 amino acid Nutrition 0.000 description 10
• 230000004663 cell proliferation Effects 0.000 description 10
• LOKCTEFSRHRXRJ-UHFFFAOYSA-I dipotassium trisodium dihydrogen phosphate hydrogen phosphate dichloride Chemical compound P(=O)(O)(O)[O-].[K+].P(=O)(O)([O-])[O-].[Na+].[Na+].[Cl-].[K+].[Cl-].[Na+] LOKCTEFSRHRXRJ-UHFFFAOYSA-I 0.000 description 10
• 239000002953 phosphate buffered saline Substances 0.000 description 10
• 230000035755 proliferation Effects 0.000 description 10
• 230000019491 signal transduction Effects 0.000 description 10
• 230000000638 stimulation Effects 0.000 description 10
• 239000003826 tablet Substances 0.000 description 10
• 238000012360 testing method Methods 0.000 description 10
• RIOQSEWOXXDEQQ-UHFFFAOYSA-N triphenylphosphine Chemical compound C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 RIOQSEWOXXDEQQ-UHFFFAOYSA-N 0.000 description 10
• HKQTYQDNCKMNHZ-UHFFFAOYSA-N 1,4-dioxaspiro[4.5]decan-8-ol Chemical compound C1CC(O)CCC21OCCO2 HKQTYQDNCKMNHZ-UHFFFAOYSA-N 0.000 description 9
• PDAICCWAUIWVHA-UHFFFAOYSA-N 1-(1,4-dioxaspiro[4.5]decan-8-yl)-3-(4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-4-amine Chemical compound C1=2C(N)=NC=NC=2N(C2CCC3(CC2)OCCO3)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 PDAICCWAUIWVHA-UHFFFAOYSA-N 0.000 description 9
• PEDCQBHIVMGVHV-UHFFFAOYSA-N Glycerine Chemical compound OCC(O)CO PEDCQBHIVMGVHV-UHFFFAOYSA-N 0.000 description 9
• VYPSYNLAJGMNEJ-UHFFFAOYSA-N Silicium dioxide Chemical compound O=[Si]=O VYPSYNLAJGMNEJ-UHFFFAOYSA-N 0.000 description 9
• ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 description 9
• 102100038232 Vascular endothelial growth factor C Human genes 0.000 description 9
• 239000002775 capsule Substances 0.000 description 9
• 230000006870 function Effects 0.000 description 9
• 239000011780 sodium chloride Substances 0.000 description 9
• 238000010561 standard procedure Methods 0.000 description 9
• 239000000126 substance Substances 0.000 description 9
• 210000003556 vascular endothelial cell Anatomy 0.000 description 9
• 108091003079 Bovine Serum Albumin Proteins 0.000 description 8
• 108010024986 Cyclin-Dependent Kinase 2 Proteins 0.000 description 8
• 102100036239 Cyclin-dependent kinase 2 Human genes 0.000 description 8
• 101150028321 Lck gene Proteins 0.000 description 8
• OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 8
• 102100037787 Protein-tyrosine kinase 2-beta Human genes 0.000 description 8
• 210000001744 T-lymphocyte Anatomy 0.000 description 8
• 239000000969 carrier Substances 0.000 description 8
• 230000001413 cellular effect Effects 0.000 description 8
• 239000003795 chemical substances by application Substances 0.000 description 8
• 239000007924 injection Substances 0.000 description 8
• 238000002347 injection Methods 0.000 description 8
• 230000003834 intracellular effect Effects 0.000 description 8
• VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 8
• 239000011976 maleic acid Substances 0.000 description 8
• 239000008194 pharmaceutical composition Substances 0.000 description 8
• 239000000843 powder Substances 0.000 description 8
• 239000002244 precipitate Substances 0.000 description 8
• 239000000047 product Substances 0.000 description 8
• 238000000746 purification Methods 0.000 description 8
• 235000017557 sodium bicarbonate Nutrition 0.000 description 8
• 229910000030 sodium bicarbonate Inorganic materials 0.000 description 8
• 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 description 8
• 210000001519 tissue Anatomy 0.000 description 8
• VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 8
• 241000701447 unidentified baculovirus Species 0.000 description 8
• 102000003903 Cyclin-dependent kinases Human genes 0.000 description 7
• 108090000266 Cyclin-dependent kinases Proteins 0.000 description 7
• XTHFKEDIFFGKHM-UHFFFAOYSA-N Dimethoxyethane Chemical compound COCCOC XTHFKEDIFFGKHM-UHFFFAOYSA-N 0.000 description 7
• 108090000315 Protein Kinase C Proteins 0.000 description 7
• 102000003923 Protein Kinase C Human genes 0.000 description 7
• 230000033228 biological regulation Effects 0.000 description 7
• 239000006184 cosolvent Substances 0.000 description 7
• 229940079593 drug Drugs 0.000 description 7
• 239000012530 fluid Substances 0.000 description 7
• 238000004519 manufacturing process Methods 0.000 description 7
• 239000002609 medium Substances 0.000 description 7
• 108091008046 non-receptor tyrosine kinases Proteins 0.000 description 7
• 102000037979 non-receptor tyrosine kinases Human genes 0.000 description 7
• 239000002773 nucleotide Substances 0.000 description 7
• 125000003729 nucleotide group Chemical group 0.000 description 7
• 239000000546 pharmaceutical excipient Substances 0.000 description 7
• 235000013855 polyvinylpyrrolidone Nutrition 0.000 description 7
• 239000001267 polyvinylpyrrolidone Substances 0.000 description 7
• 229920000036 polyvinylpyrrolidone Polymers 0.000 description 7
• 230000002062 proliferating effect Effects 0.000 description 7
• 238000010992 reflux Methods 0.000 description 7
• 238000011160 research Methods 0.000 description 7
• YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 7
• 229940121358 tyrosine kinase inhibitor Drugs 0.000 description 7
• YYVUOZULIDAKRN-UHFFFAOYSA-N 3-(4-phenoxyphenyl)-2h-pyrazolo[3,4-d]pyrimidin-4-amine Chemical compound C=12C(N)=NC=NC2=NNC=1C(C=C1)=CC=C1OC1=CC=CC=C1 YYVUOZULIDAKRN-UHFFFAOYSA-N 0.000 description 6
• JZKQVYDRZSOJBP-UHFFFAOYSA-N 4-[4-amino-3-(4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-1-yl]cyclohexan-1-one Chemical compound C1=2C(N)=NC=NC=2N(C2CCC(=O)CC2)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 JZKQVYDRZSOJBP-UHFFFAOYSA-N 0.000 description 6
• WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 description 6
• VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 description 6
• 101100464293 Caenorhabditis elegans plk-1 gene Proteins 0.000 description 6
• 101000692455 Homo sapiens Platelet-derived growth factor receptor beta Proteins 0.000 description 6
• 101000818543 Homo sapiens Tyrosine-protein kinase ZAP-70 Proteins 0.000 description 6
• OUYCCCASQSFEME-QMMMGPOBSA-N L-tyrosine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-QMMMGPOBSA-N 0.000 description 6
• GUBGYTABKSRVRQ-QKKXKWKRSA-N Lactose Natural products OC[C@H]1O[C@@H](O[C@H]2[C@H](O)[C@@H](O)C(O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@H]1O GUBGYTABKSRVRQ-QKKXKWKRSA-N 0.000 description 6
• 102100026547 Platelet-derived growth factor receptor beta Human genes 0.000 description 6
• CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 6
• 229920002472 Starch Polymers 0.000 description 6
• 102100038234 Vascular endothelial growth factor D Human genes 0.000 description 6
• 229940098773 bovine serum albumin Drugs 0.000 description 6
• 239000012267 brine Substances 0.000 description 6
• 229940125773 compound 10 Drugs 0.000 description 6
• 230000001419 dependent effect Effects 0.000 description 6
• 230000008021 deposition Effects 0.000 description 6
• 238000001704 evaporation Methods 0.000 description 6
• 230000008020 evaporation Effects 0.000 description 6
• 239000000706 filtrate Substances 0.000 description 6
• IXCSERBJSXMMFS-UHFFFAOYSA-N hydrogen chloride Substances Cl.Cl IXCSERBJSXMMFS-UHFFFAOYSA-N 0.000 description 6
• 229910000041 hydrogen chloride Inorganic materials 0.000 description 6
• RAXXELZNTBOGNW-UHFFFAOYSA-N imidazole Natural products C1=CNC=N1 RAXXELZNTBOGNW-UHFFFAOYSA-N 0.000 description 6
• 230000003993 interaction Effects 0.000 description 6
• ZLVXBBHTMQJRSX-VMGNSXQWSA-N jdtic Chemical compound C1([C@]2(C)CCN(C[C@@H]2C)C[C@H](C(C)C)NC(=O)[C@@H]2NCC3=CC(O)=CC=C3C2)=CC=CC(O)=C1 ZLVXBBHTMQJRSX-VMGNSXQWSA-N 0.000 description 6
• 229940043355 kinase inhibitor Drugs 0.000 description 6
• 239000008101 lactose Substances 0.000 description 6
• HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 6
• 239000011159 matrix material Substances 0.000 description 6
• KDLHZDBZIXYQEI-UHFFFAOYSA-N palladium Substances [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 6
• YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 6
• 239000003757 phosphotransferase inhibitor Substances 0.000 description 6
• 229920000728 polyester Polymers 0.000 description 6
• 108090000765 processed proteins & peptides Proteins 0.000 description 6
• 230000001105 regulatory effect Effects 0.000 description 6
• 239000000741 silica gel Substances 0.000 description 6
• 229910002027 silica gel Inorganic materials 0.000 description 6
• 229960001866 silicon dioxide Drugs 0.000 description 6
• HPALAKNZSZLMCH-UHFFFAOYSA-M sodium;chloride;hydrate Chemical compound O.[Na+].[Cl-] HPALAKNZSZLMCH-UHFFFAOYSA-M 0.000 description 6
• 230000001988 toxicity Effects 0.000 description 6
• 231100000419 toxicity Toxicity 0.000 description 6
• 239000005483 tyrosine kinase inhibitor Substances 0.000 description 6
• 238000005406 washing Methods 0.000 description 6
• GLGNXYJARSMNGJ-VKTIVEEGSA-N (1s,2s,3r,4r)-3-[[5-chloro-2-[(1-ethyl-6-methoxy-2-oxo-4,5-dihydro-3h-1-benzazepin-7-yl)amino]pyrimidin-4-yl]amino]bicyclo[2.2.1]hept-5-ene-2-carboxamide Chemical compound CCN1C(=O)CCCC2=C(OC)C(NC=3N=C(C(=CN=3)Cl)N[C@H]3[C@H]([C@@]4([H])C[C@@]3(C=C4)[H])C(N)=O)=CC=C21 GLGNXYJARSMNGJ-VKTIVEEGSA-N 0.000 description 5
• WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 description 5
• PVOAHINGSUIXLS-UHFFFAOYSA-N 1-Methylpiperazine Chemical compound CN1CCNCC1 PVOAHINGSUIXLS-UHFFFAOYSA-N 0.000 description 5
• JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 5
• HBAQYPYDRFILMT-UHFFFAOYSA-N 8-[3-(1-cyclopropylpyrazol-4-yl)-1H-pyrazolo[4,3-d]pyrimidin-5-yl]-3-methyl-3,8-diazabicyclo[3.2.1]octan-2-one Chemical class C1(CC1)N1N=CC(=C1)C1=NNC2=C1N=C(N=C2)N1C2C(N(CC1CC2)C)=O HBAQYPYDRFILMT-UHFFFAOYSA-N 0.000 description 5
• 101100059559 Emericella nidulans (strain FGSC A4 / ATCC 38163 / CBS 112.46 / NRRL 194 / M139) nimX gene Proteins 0.000 description 5
• 206010015866 Extravasation Diseases 0.000 description 5
• 108091008794 FGF receptors Proteins 0.000 description 5
• 108010010803 Gelatin Proteins 0.000 description 5
• 101000595923 Homo sapiens Placenta growth factor Proteins 0.000 description 5
• 101000851007 Homo sapiens Vascular endothelial growth factor receptor 2 Proteins 0.000 description 5
• 108010002350 Interleukin-2 Proteins 0.000 description 5
• 102000000588 Interleukin-2 Human genes 0.000 description 5
• 206010027476 Metastases Diseases 0.000 description 5
• 108700020796 Oncogene Proteins 0.000 description 5
• 235000008331 Pinus X rigitaeda Nutrition 0.000 description 5
• 235000011613 Pinus brutia Nutrition 0.000 description 5
• 241000018646 Pinus brutia Species 0.000 description 5
• 102100035194 Placenta growth factor Human genes 0.000 description 5
• 102100021125 Tyrosine-protein kinase ZAP-70 Human genes 0.000 description 5
• 101100273808 Xenopus laevis cdk1-b gene Proteins 0.000 description 5
• 239000004480 active ingredient Substances 0.000 description 5
• 230000001154 acute effect Effects 0.000 description 5
• 125000001931 aliphatic group Chemical group 0.000 description 5
• 229910000147 aluminium phosphate Inorganic materials 0.000 description 5
• 230000000903 blocking effect Effects 0.000 description 5
• 238000004113 cell culture Methods 0.000 description 5
• 239000012230 colorless oil Substances 0.000 description 5
• 229940125758 compound 15 Drugs 0.000 description 5
• 238000001816 cooling Methods 0.000 description 5
• 230000004069 differentiation Effects 0.000 description 5
• 230000003511 endothelial effect Effects 0.000 description 5
• 230000036251 extravasation Effects 0.000 description 5
• 102000052178 fibroblast growth factor receptor activity proteins Human genes 0.000 description 5
• 239000008273 gelatin Substances 0.000 description 5
• 229920000159 gelatin Polymers 0.000 description 5
• 229940014259 gelatin Drugs 0.000 description 5
• 235000019322 gelatine Nutrition 0.000 description 5
• 235000011852 gelatine desserts Nutrition 0.000 description 5
• 239000012362 glacial acetic acid Substances 0.000 description 5
• 230000012010 growth Effects 0.000 description 5
• 230000002209 hydrophobic effect Effects 0.000 description 5
• 238000000338 in vitro Methods 0.000 description 5
• 239000007788 liquid Substances 0.000 description 5
• 229920001223 polyethylene glycol Polymers 0.000 description 5
• 230000005855 radiation Effects 0.000 description 5
• 238000012552 review Methods 0.000 description 5
• 235000019698 starch Nutrition 0.000 description 5
• 239000000829 suppository Substances 0.000 description 5
• 230000008728 vascular permeability Effects 0.000 description 5
• KFXUHRXGLWUOJT-UHFFFAOYSA-N (4-phenoxyphenyl)boronic acid Chemical compound C1=CC(B(O)O)=CC=C1OC1=CC=CC=C1 KFXUHRXGLWUOJT-UHFFFAOYSA-N 0.000 description 4
• ZPLZIUYGGZJZML-UKFGXMPHSA-N (Z)-but-2-enedioic acid 3-(4-phenoxyphenyl)-1-[1-(1-propan-2-ylpiperidin-4-yl)piperidin-4-yl]pyrazolo[3,4-d]pyrimidin-4-amine Chemical compound OC(=O)\C=C/C(O)=O.OC(=O)\C=C/C(O)=O.OC(=O)\C=C/C(O)=O.CC(C)N1CCC(CC1)N1CCC(CC1)n1nc(-c2ccc(Oc3ccccc3)cc2)c2c(N)ncnc12 ZPLZIUYGGZJZML-UKFGXMPHSA-N 0.000 description 4
• FUOOLUPWFVMBKG-UHFFFAOYSA-N 2-Aminoisobutyric acid Chemical compound CC(C)(N)C(O)=O FUOOLUPWFVMBKG-UHFFFAOYSA-N 0.000 description 4
• LHCPRYRLDOSKHK-UHFFFAOYSA-N 7-deaza-8-aza-adenine Chemical compound NC1=NC=NC2=C1C=NN2 LHCPRYRLDOSKHK-UHFFFAOYSA-N 0.000 description 4
• 206010001052 Acute respiratory distress syndrome Diseases 0.000 description 4
• 102100034608 Angiopoietin-2 Human genes 0.000 description 4
• 206010003445 Ascites Diseases 0.000 description 4
• 208000023275 Autoimmune disease Diseases 0.000 description 4
• HPKFKTUMVCAXKV-IPZLUAPPSA-N C(C(O)CC(=O)O)(=O)O.C(C(O)CC(=O)O)(=O)O.CN1CCN(CC1)[C@@H]1CC[C@H](CC1)N1N=C(C=2C1=NC=NC2N)C2=CC=C(C=C2)OC2=CC=CC=C2 Chemical compound C(C(O)CC(=O)O)(=O)O.C(C(O)CC(=O)O)(=O)O.CN1CCN(CC1)[C@@H]1CC[C@H](CC1)N1N=C(C=2C1=NC=NC2N)C2=CC=C(C=C2)OC2=CC=CC=C2 HPKFKTUMVCAXKV-IPZLUAPPSA-N 0.000 description 4
• CURLTUGMZLYLDI-UHFFFAOYSA-N Carbon dioxide Chemical compound O=C=O CURLTUGMZLYLDI-UHFFFAOYSA-N 0.000 description 4
• 208000005623 Carcinogenesis Diseases 0.000 description 4
• 102000002427 Cyclin B Human genes 0.000 description 4
• 108010068150 Cyclin B Proteins 0.000 description 4
• 208000009386 Experimental Arthritis Diseases 0.000 description 4
• 102100031706 Fibroblast growth factor 1 Human genes 0.000 description 4
• ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 4
• WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Chemical compound OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 4
• 239000007995 HEPES buffer Substances 0.000 description 4
• 101000808011 Homo sapiens Vascular endothelial growth factor A Proteins 0.000 description 4
• 241000699666 Mus <mouse, genus> Species 0.000 description 4
• FXHOOIRPVKKKFG-UHFFFAOYSA-N N,N-Dimethylacetamide Chemical compound CN(C)C(C)=O FXHOOIRPVKKKFG-UHFFFAOYSA-N 0.000 description 4
• LQZMLBORDGWNPD-UHFFFAOYSA-N N-iodosuccinimide Chemical compound IN1C(=O)CCC1=O LQZMLBORDGWNPD-UHFFFAOYSA-N 0.000 description 4
• JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 description 4
• CZPWVGJYEJSRLH-UHFFFAOYSA-N Pyrimidine Chemical compound C1=CN=CN=C1 CZPWVGJYEJSRLH-UHFFFAOYSA-N 0.000 description 4
• 241000700159 Rattus Species 0.000 description 4
• 208000013616 Respiratory Distress Syndrome Diseases 0.000 description 4
• 230000018199 S phase Effects 0.000 description 4
• DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 4
• 239000007983 Tris buffer Substances 0.000 description 4
• 102000009484 Vascular Endothelial Growth Factor Receptors Human genes 0.000 description 4
• 102100033179 Vascular endothelial growth factor receptor 3 Human genes 0.000 description 4
• 239000002253 acid Substances 0.000 description 4
• 239000013543 active substance Substances 0.000 description 4
• 208000011341 adult acute respiratory distress syndrome Diseases 0.000 description 4
• 201000000028 adult respiratory distress syndrome Diseases 0.000 description 4
• QGZKDVFQNNGYKY-UHFFFAOYSA-N ammonia Natural products N QGZKDVFQNNGYKY-UHFFFAOYSA-N 0.000 description 4
• 239000000908 ammonium hydroxide Substances 0.000 description 4
• 238000010171 animal model Methods 0.000 description 4
• 239000005557 antagonist Substances 0.000 description 4
• 239000000427 antigen Substances 0.000 description 4
• 108091007433 antigens Proteins 0.000 description 4
• 102000036639 antigens Human genes 0.000 description 4
• 239000007864 aqueous solution Substances 0.000 description 4
• 206010003246 arthritis Diseases 0.000 description 4
• 239000002585 base Substances 0.000 description 4
• 230000004071 biological effect Effects 0.000 description 4
• 210000004204 blood vessel Anatomy 0.000 description 4
• 230000036952 cancer formation Effects 0.000 description 4
• 231100000504 carcinogenesis Toxicity 0.000 description 4
• 230000022131 cell cycle Effects 0.000 description 4
• 238000004891 communication Methods 0.000 description 4
• 239000002299 complementary DNA Substances 0.000 description 4
• 238000011161 development Methods 0.000 description 4
• 230000018109 developmental process Effects 0.000 description 4
• FAMRKDQNMBBFBR-BQYQJAHWSA-N diethyl azodicarboxylate Substances CCOC(=O)\N=N\C(=O)OCC FAMRKDQNMBBFBR-BQYQJAHWSA-N 0.000 description 4
• 239000008298 dragée Substances 0.000 description 4
• 239000000839 emulsion Substances 0.000 description 4
• 102000052116 epidermal growth factor receptor activity proteins Human genes 0.000 description 4
• 108700015053 epidermal growth factor receptor activity proteins Proteins 0.000 description 4
• FAMRKDQNMBBFBR-UHFFFAOYSA-N ethyl n-ethoxycarbonyliminocarbamate Chemical compound CCOC(=O)N=NC(=O)OCC FAMRKDQNMBBFBR-UHFFFAOYSA-N 0.000 description 4
• 239000000284 extract Substances 0.000 description 4
• 102000058223 human VEGFA Human genes 0.000 description 4
• 230000003053 immunization Effects 0.000 description 4
• 238000002649 immunization Methods 0.000 description 4
• 230000002779 inactivation Effects 0.000 description 4
• 238000011534 incubation Methods 0.000 description 4
• 238000007912 intraperitoneal administration Methods 0.000 description 4
• 239000000463 material Substances 0.000 description 4
• 231100000682 maximum tolerated dose Toxicity 0.000 description 4
• 230000009401 metastasis Effects 0.000 description 4
• 238000013508 migration Methods 0.000 description 4
• YOHYSYJDKVYCJI-UHFFFAOYSA-N n-[3-[[6-[3-(trifluoromethyl)anilino]pyrimidin-4-yl]amino]phenyl]cyclopropanecarboxamide Chemical compound FC(F)(F)C1=CC=CC(NC=2N=CN=C(NC=3C=C(NC(=O)C4CC4)C=CC=3)C=2)=C1 YOHYSYJDKVYCJI-UHFFFAOYSA-N 0.000 description 4
• 239000000825 pharmaceutical preparation Substances 0.000 description 4
• 230000036470 plasma concentration Effects 0.000 description 4
• SCVFZCLFOSHCOH-UHFFFAOYSA-M potassium acetate Chemical compound [K+].CC([O-])=O SCVFZCLFOSHCOH-UHFFFAOYSA-M 0.000 description 4
• 230000003389 potentiating effect Effects 0.000 description 4
• 210000002966 serum Anatomy 0.000 description 4
• 230000011664 signaling Effects 0.000 description 4
• 229910000104 sodium hydride Inorganic materials 0.000 description 4
• 239000003381 stabilizer Substances 0.000 description 4
• 125000005504 styryl group Chemical group 0.000 description 4
• 235000000346 sugar Nutrition 0.000 description 4
• 238000013268 sustained release Methods 0.000 description 4
• 239000012730 sustained-release form Substances 0.000 description 4
• FYSNRJHAOHDILO-UHFFFAOYSA-N thionyl chloride Chemical compound ClS(Cl)=O FYSNRJHAOHDILO-UHFFFAOYSA-N 0.000 description 4
• 230000008733 trauma Effects 0.000 description 4
• LENZDBCJOHFCAS-UHFFFAOYSA-N tris Chemical compound OCC(N)(CO)CO LENZDBCJOHFCAS-UHFFFAOYSA-N 0.000 description 4
• 235000002374 tyrosine Nutrition 0.000 description 4
• 125000001493 tyrosinyl group Chemical group [H]OC1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])(N([H])[H])C(*)=O 0.000 description 4
• 210000004291 uterus Anatomy 0.000 description 4
• DGVVWUTYPXICAM-UHFFFAOYSA-N β‐Mercaptoethanol Chemical compound OCCS DGVVWUTYPXICAM-UHFFFAOYSA-N 0.000 description 4
• MTCFGRXMJLQNBG-REOHCLBHSA-N (2S)-2-Amino-3-hydroxypropansäure Chemical compound OC[C@H](N)C(O)=O MTCFGRXMJLQNBG-REOHCLBHSA-N 0.000 description 3
• WGFWGBBWNNCSRI-UKFGXMPHSA-N (Z)-but-2-enedioic acid 1-[4-(4-methylpiperazin-1-yl)cyclohexyl]-3-(4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-4-amine Chemical compound OC(=O)\C=C/C(O)=O.OC(=O)\C=C/C(O)=O.OC(=O)\C=C/C(O)=O.C1CN(C)CCN1C1CCC(N2C3=NC=NC(N)=C3C(C=3C=CC(OC=4C=CC=CC=4)=CC=3)=N2)CC1 WGFWGBBWNNCSRI-UKFGXMPHSA-N 0.000 description 3
• SCYULBFZEHDVBN-UHFFFAOYSA-N 1,1-Dichloroethane Chemical compound CC(Cl)Cl SCYULBFZEHDVBN-UHFFFAOYSA-N 0.000 description 3
• RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 description 3
• VKRKCBWIVLSRBJ-UHFFFAOYSA-N 1,4-dioxaspiro[4.5]decan-8-one Chemical compound C1CC(=O)CCC21OCCO2 VKRKCBWIVLSRBJ-UHFFFAOYSA-N 0.000 description 3
• OWOKCUXVMOFUSP-UHFFFAOYSA-N 1,4-dioxaspiro[4.5]decan-8-yl 4-methylbenzenesulfonate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)OC1CCC2(OCCO2)CC1 OWOKCUXVMOFUSP-UHFFFAOYSA-N 0.000 description 3
• IRVRZQLHMPWLLY-UHFFFAOYSA-N 2-[methoxy-(4-phenoxyphenyl)methylidene]propanedinitrile Chemical compound C1=CC(C(=C(C#N)C#N)OC)=CC=C1OC1=CC=CC=C1 IRVRZQLHMPWLLY-UHFFFAOYSA-N 0.000 description 3
• UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 3
• LGWZZMCTBPCKHR-UHFFFAOYSA-N 3-(4-phenoxyphenyl)-1-piperidin-4-ylpyrazolo[3,4-d]pyrimidin-4-amine Chemical compound C1=2C(N)=NC=NC=2N(C2CCNCC2)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 LGWZZMCTBPCKHR-UHFFFAOYSA-N 0.000 description 3
• HNIMEQCLCNSCGH-UHFFFAOYSA-N 3-amino-5-(4-phenoxyphenyl)-1h-pyrazole-4-carbonitrile Chemical compound NC1=NNC(C=2C=CC(OC=3C=CC=CC=3)=CC=2)=C1C#N HNIMEQCLCNSCGH-UHFFFAOYSA-N 0.000 description 3
• LZLZSMSXXYHORJ-UHFFFAOYSA-N 3-bromo-1-(1,4-dioxaspiro[4.5]decan-8-yl)pyrazolo[3,4-d]pyrimidin-4-amine Chemical compound N1=C(Br)C=2C(N)=NC=NC=2N1C(CC1)CCC21OCCO2 LZLZSMSXXYHORJ-UHFFFAOYSA-N 0.000 description 3
• MDFHFCAMBZNSLV-UHFFFAOYSA-N 3-bromo-4-chloro-2h-pyrazolo[3,4-d]pyrimidine Chemical compound ClC1=NC=NC2=NNC(Br)=C12 MDFHFCAMBZNSLV-UHFFFAOYSA-N 0.000 description 3
• LFTXIWVMFHWGNH-UHFFFAOYSA-N 4-(4-amino-3-iodopyrazolo[3,4-d]pyrimidin-1-yl)cyclohexan-1-one Chemical compound N1=C(I)C=2C(N)=NC=NC=2N1C1CCC(=O)CC1 LFTXIWVMFHWGNH-UHFFFAOYSA-N 0.000 description 3
• LFLSATHZMYYIAQ-UHFFFAOYSA-N 4-flourobenzenesulfonamide Chemical compound NS(=O)(=O)C1=CC=C(F)C=C1 LFLSATHZMYYIAQ-UHFFFAOYSA-N 0.000 description 3
• 125000002373 5 membered heterocyclic group Chemical group 0.000 description 3
• 102100034594 Angiopoietin-1 Human genes 0.000 description 3
• 108010039627 Aprotinin Proteins 0.000 description 3
• 206010048962 Brain oedema Diseases 0.000 description 3
• 208000026310 Breast neoplasm Diseases 0.000 description 3
• KXDHJXZQYSOELW-UHFFFAOYSA-M Carbamate Chemical compound NC([O-])=O KXDHJXZQYSOELW-UHFFFAOYSA-M 0.000 description 3
• 102000016736 Cyclin Human genes 0.000 description 3
• 108050006400 Cyclin Proteins 0.000 description 3
• 102000004127 Cytokines Human genes 0.000 description 3
• 108090000695 Cytokines Proteins 0.000 description 3
• FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 3
• FBPFZTCFMRRESA-JGWLITMVSA-N D-glucitol Chemical compound OC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-JGWLITMVSA-N 0.000 description 3
• 206010061818 Disease progression Diseases 0.000 description 3
• 206010063045 Effusion Diseases 0.000 description 3
• WHUUTDBJXJRKMK-UHFFFAOYSA-N Glutamic acid Natural products OC(=O)C(N)CCC(O)=O WHUUTDBJXJRKMK-UHFFFAOYSA-N 0.000 description 3
• HTTJABKRGRZYRN-UHFFFAOYSA-N Heparin Chemical compound OC1C(NC(=O)C)C(O)OC(COS(O)(=O)=O)C1OC1C(OS(O)(=O)=O)C(O)C(OC2C(C(OS(O)(=O)=O)C(OC3C(C(O)C(O)C(O3)C(O)=O)OS(O)(=O)=O)C(CO)O2)NS(O)(=O)=O)C(C(O)=O)O1 HTTJABKRGRZYRN-UHFFFAOYSA-N 0.000 description 3
• 101000924533 Homo sapiens Angiopoietin-2 Proteins 0.000 description 3
• 108010074328 Interferon-gamma Proteins 0.000 description 3
• 208000019693 Lung disease Diseases 0.000 description 3
• 206010025538 Malignant ascites Diseases 0.000 description 3
• 241000124008 Mammalia Species 0.000 description 3
• 108020005497 Nuclear hormone receptor Proteins 0.000 description 3
• 208000001132 Osteoporosis Diseases 0.000 description 3
• 239000002202 Polyethylene glycol Substances 0.000 description 3
• 108010029485 Protein Isoforms Proteins 0.000 description 3
• 102000001708 Protein Isoforms Human genes 0.000 description 3
• 102000004278 Receptor Protein-Tyrosine Kinases Human genes 0.000 description 3
• 108090000873 Receptor Protein-Tyrosine Kinases Proteins 0.000 description 3
• KEAYESYHFKHZAL-UHFFFAOYSA-N Sodium Chemical compound [Na] KEAYESYHFKHZAL-UHFFFAOYSA-N 0.000 description 3
• PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 3
• FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric Acid Chemical class [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 3
• 239000013504 Triton X-100 Substances 0.000 description 3
• 229920004890 Triton X-100 Polymers 0.000 description 3
• 230000001594 aberrant effect Effects 0.000 description 3
• 150000007513 acids Chemical class 0.000 description 3
• 239000012190 activator Substances 0.000 description 3
• 206010064930 age-related macular degeneration Diseases 0.000 description 3
• 230000001772 anti-angiogenic effect Effects 0.000 description 3
• 238000013459 approach Methods 0.000 description 3
• 229960004405 aprotinin Drugs 0.000 description 3
• 230000035578 autophosphorylation Effects 0.000 description 3
• 210000000988 bone and bone Anatomy 0.000 description 3
• 208000006752 brain edema Diseases 0.000 description 3
• 230000006369 cell cycle progression Effects 0.000 description 3
• 230000033077 cellular process Effects 0.000 description 3
• 230000002490 cerebral effect Effects 0.000 description 3
• 229940125782 compound 2 Drugs 0.000 description 3
• 238000002425 crystallisation Methods 0.000 description 3
• 230000008025 crystallization Effects 0.000 description 3
• MFTWJSCJPWZDNV-UHFFFAOYSA-N cyclohexyl piperazine-1-carboxylate Chemical compound C1CNCCN1C(=O)OC1CCCCC1 MFTWJSCJPWZDNV-UHFFFAOYSA-N 0.000 description 3
• 230000001086 cytosolic effect Effects 0.000 description 3
• 238000010790 dilution Methods 0.000 description 3
• 239000012895 dilution Substances 0.000 description 3
• 230000005750 disease progression Effects 0.000 description 3
• 239000002552 dosage form Substances 0.000 description 3
• 239000003937 drug carrier Substances 0.000 description 3
• 239000003480 eluent Substances 0.000 description 3
• 201000002491 encephalomyelitis Diseases 0.000 description 3
• 150000002148 esters Chemical class 0.000 description 3
• 229940011871 estrogen Drugs 0.000 description 3
• 239000000262 estrogen Substances 0.000 description 3
• DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 3
• 238000002474 experimental method Methods 0.000 description 3
• 210000000416 exudates and transudate Anatomy 0.000 description 3
• 239000000499 gel Substances 0.000 description 3
• 238000010438 heat treatment Methods 0.000 description 3
• 229920000669 heparin Polymers 0.000 description 3
• 229960002897 heparin Drugs 0.000 description 3
• 208000026278 immune system disease Diseases 0.000 description 3
• ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 3
• 210000003734 kidney Anatomy 0.000 description 3
• 239000002502 liposome Substances 0.000 description 3
• 239000006166 lysate Substances 0.000 description 3
• 235000019359 magnesium stearate Nutrition 0.000 description 3
• 150000002688 maleic acid derivatives Chemical class 0.000 description 3
• 108020004999 messenger RNA Proteins 0.000 description 3
• 238000004452 microanalysis Methods 0.000 description 3
• 238000010172 mouse model Methods 0.000 description 3
• 230000035772 mutation Effects 0.000 description 3
• 230000001613 neoplastic effect Effects 0.000 description 3
• 231100000590 oncogenic Toxicity 0.000 description 3
• 230000002246 oncogenic effect Effects 0.000 description 3
• 210000000056 organ Anatomy 0.000 description 3
• 239000003960 organic solvent Substances 0.000 description 3
• NFHFRUOZVGFOOS-UHFFFAOYSA-N palladium;triphenylphosphane Chemical compound [Pd].C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1.C1=CC=CC=C1P(C=1C=CC=CC=1)C1=CC=CC=C1 NFHFRUOZVGFOOS-UHFFFAOYSA-N 0.000 description 3
• 239000003208 petroleum Substances 0.000 description 3
• 239000008177 pharmaceutical agent Substances 0.000 description 3
• DCWXELXMIBXGTH-UHFFFAOYSA-N phosphotyrosine Chemical compound OC(=O)C(N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-UHFFFAOYSA-N 0.000 description 3
• 125000004482 piperidin-4-yl group Chemical group N1CCC(CC1)* 0.000 description 3
• 238000012545 processing Methods 0.000 description 3
• 230000001737 promoting effect Effects 0.000 description 3
• 239000011535 reaction buffer Substances 0.000 description 3
• 229940001593 sodium carbonate Drugs 0.000 description 3
• 229910000029 sodium carbonate Inorganic materials 0.000 description 3
• 239000012312 sodium hydride Substances 0.000 description 3
• 229910052938 sodium sulfate Inorganic materials 0.000 description 3
• 235000011152 sodium sulphate Nutrition 0.000 description 3
• 239000012453 solvate Substances 0.000 description 3
• 239000000600 sorbitol Substances 0.000 description 3
• 239000008107 starch Substances 0.000 description 3
• 238000003860 storage Methods 0.000 description 3
• 238000006467 substitution reaction Methods 0.000 description 3
• 150000008163 sugars Chemical class 0.000 description 3
• 239000004094 surface-active agent Substances 0.000 description 3
• 239000006188 syrup Substances 0.000 description 3
• 235000020357 syrup Nutrition 0.000 description 3
• 238000012546 transfer Methods 0.000 description 3
• OUYCCCASQSFEME-UHFFFAOYSA-N tyrosine Natural products OC(=O)C(N)CC1=CC=C(O)C=C1 OUYCCCASQSFEME-UHFFFAOYSA-N 0.000 description 3
• 238000001262 western blot Methods 0.000 description 3
• GHYOCDFICYLMRF-UTIIJYGPSA-N (2S,3R)-N-[(2S)-3-(cyclopenten-1-yl)-1-[(2R)-2-methyloxiran-2-yl]-1-oxopropan-2-yl]-3-hydroxy-3-(4-methoxyphenyl)-2-[[(2S)-2-[(2-morpholin-4-ylacetyl)amino]propanoyl]amino]propanamide Chemical compound C1(=CCCC1)C[C@@H](C(=O)[C@@]1(OC1)C)NC([C@H]([C@@H](C1=CC=C(C=C1)OC)O)NC([C@H](C)NC(CN1CCOCC1)=O)=O)=O GHYOCDFICYLMRF-UTIIJYGPSA-N 0.000 description 2
• QFLWZFQWSBQYPS-AWRAUJHKSA-N (3S)-3-[[(2S)-2-[[(2S)-2-[5-[(3aS,6aR)-2-oxo-1,3,3a,4,6,6a-hexahydrothieno[3,4-d]imidazol-4-yl]pentanoylamino]-3-methylbutanoyl]amino]-3-(4-hydroxyphenyl)propanoyl]amino]-4-[1-bis(4-chlorophenoxy)phosphorylbutylamino]-4-oxobutanoic acid Chemical compound CCCC(NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](Cc1ccc(O)cc1)NC(=O)[C@@H](NC(=O)CCCCC1SC[C@@H]2NC(=O)N[C@H]12)C(C)C)P(=O)(Oc1ccc(Cl)cc1)Oc1ccc(Cl)cc1 QFLWZFQWSBQYPS-AWRAUJHKSA-N 0.000 description 2
• GNSWZAOTVNDBQM-UHFFFAOYSA-N 1-(1,4-dioxaspiro[4.5]decan-8-yl)-3-iodopyrazolo[3,4-d]pyrimidin-4-amine Chemical compound N1=C(I)C=2C(N)=NC=NC=2N1C(CC1)CCC21OCCO2 GNSWZAOTVNDBQM-UHFFFAOYSA-N 0.000 description 2
• XZIQETGYQKIMSS-UHFFFAOYSA-N 1-(1-benzylpiperidin-4-yl)-3-(4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-4-amine Chemical compound C1=2C(N)=NC=NC=2N(C2CCN(CC=3C=CC=CC=3)CC2)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 XZIQETGYQKIMSS-UHFFFAOYSA-N 0.000 description 2
• HJOMLGKVFCHOCJ-UHFFFAOYSA-N 1-(1-benzylpiperidin-4-yl)-3-bromo-4-chloropyrazolo[3,4-d]pyrimidine Chemical compound N1=C(Br)C=2C(Cl)=NC=NC=2N1C(CC1)CCN1CC1=CC=CC=C1 HJOMLGKVFCHOCJ-UHFFFAOYSA-N 0.000 description 2
• PBLZLIFKVPJDCO-UHFFFAOYSA-N 12-aminododecanoic acid Chemical compound NCCCCCCCCCCCC(O)=O PBLZLIFKVPJDCO-UHFFFAOYSA-N 0.000 description 2
• BAXOFTOLAUCFNW-UHFFFAOYSA-N 1H-indazole Chemical compound C1=CC=C2C=NNC2=C1 BAXOFTOLAUCFNW-UHFFFAOYSA-N 0.000 description 2
• DNCYBUMDUBHIJZ-UHFFFAOYSA-N 1h-pyrimidin-6-one Chemical compound O=C1C=CN=CN1 DNCYBUMDUBHIJZ-UHFFFAOYSA-N 0.000 description 2
• NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 2
• KISWVXRQTGLFGD-UHFFFAOYSA-N 2-[[2-[[6-amino-2-[[2-[[2-[[5-amino-2-[[2-[[1-[2-[[6-amino-2-[(2,5-diamino-5-oxopentanoyl)amino]hexanoyl]amino]-5-(diaminomethylideneamino)pentanoyl]pyrrolidine-2-carbonyl]amino]-3-hydroxypropanoyl]amino]-5-oxopentanoyl]amino]-5-(diaminomethylideneamino)p Chemical compound C1CCN(C(=O)C(CCCN=C(N)N)NC(=O)C(CCCCN)NC(=O)C(N)CCC(N)=O)C1C(=O)NC(CO)C(=O)NC(CCC(N)=O)C(=O)NC(CCCN=C(N)N)C(=O)NC(CO)C(=O)NC(CCCCN)C(=O)NC(C(=O)NC(CC(C)C)C(O)=O)CC1=CC=C(O)C=C1 KISWVXRQTGLFGD-UHFFFAOYSA-N 0.000 description 2
• MWTPPIZIKZHMSK-UHFFFAOYSA-N 2-[hydroxy-(4-phenoxyphenyl)methylidene]propanedinitrile Chemical compound C1=CC(C(=C(C#N)C#N)O)=CC=C1OC1=CC=CC=C1 MWTPPIZIKZHMSK-UHFFFAOYSA-N 0.000 description 2
• QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
• ZHLPWZARHHYXDV-UHFFFAOYSA-N 3-(4-amino-3-fluorophenyl)-1-[4-(4-methylpiperazin-1-yl)cyclohexyl]pyrazolo[3,4-d]pyrimidin-4-amine Chemical compound C1CN(C)CCN1C1CCC(N2C3=NC=NC(N)=C3C(C=3C=C(F)C(N)=CC=3)=N2)CC1 ZHLPWZARHHYXDV-UHFFFAOYSA-N 0.000 description 2
• KAHCKNUEZSETEP-UHFFFAOYSA-N 3-bromo-1,2-dihydropyrazolo[3,4-d]pyrimidin-4-one Chemical compound C1=NC(=O)C2=C(Br)NNC2=N1 KAHCKNUEZSETEP-UHFFFAOYSA-N 0.000 description 2
• HDUXUXMOYANEGL-UHFFFAOYSA-N 3-bromo-4-chloro-1-(1,4-dioxaspiro[4.5]decan-8-yl)pyrazolo[3,4-d]pyrimidine Chemical compound N1=C(Br)C=2C(Cl)=NC=NC=2N1C(CC1)CCC21OCCO2 HDUXUXMOYANEGL-UHFFFAOYSA-N 0.000 description 2
• YURZZKWHAXPNBQ-UHFFFAOYSA-N 4-[4-amino-3-(4-amino-3-fluorophenyl)pyrazolo[3,4-d]pyrimidin-1-yl]cyclohexan-1-one Chemical compound C1=C(F)C(N)=CC=C1C(C1=C(N)N=CN=C11)=NN1C1CCC(=O)CC1 YURZZKWHAXPNBQ-UHFFFAOYSA-N 0.000 description 2
• BFXHJFKKRGVUMU-UHFFFAOYSA-N 4-fluorobenzenesulfonyl chloride Chemical compound FC1=CC=C(S(Cl)(=O)=O)C=C1 BFXHJFKKRGVUMU-UHFFFAOYSA-N 0.000 description 2
• YYROPELSRYBVMQ-UHFFFAOYSA-N 4-toluenesulfonyl chloride Chemical compound CC1=CC=C(S(Cl)(=O)=O)C=C1 YYROPELSRYBVMQ-UHFFFAOYSA-N 0.000 description 2
• JJMDCOVWQOJGCB-UHFFFAOYSA-N 5-aminopentanoic acid Chemical compound [NH3+]CCCCC([O-])=O JJMDCOVWQOJGCB-UHFFFAOYSA-N 0.000 description 2
• KDCGOANMDULRCW-UHFFFAOYSA-N 7H-purine Chemical compound N1=CNC2=NC=NC2=C1 KDCGOANMDULRCW-UHFFFAOYSA-N 0.000 description 2
• GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 2
• USFZMSVCRYTOJT-UHFFFAOYSA-N Ammonium acetate Chemical compound N.CC(O)=O USFZMSVCRYTOJT-UHFFFAOYSA-N 0.000 description 2
• 239000005695 Ammonium acetate Substances 0.000 description 2
• 108010009906 Angiopoietins Proteins 0.000 description 2
• 102000009840 Angiopoietins Human genes 0.000 description 2
• 201000004569 Blindness Diseases 0.000 description 2
• 206010006187 Breast cancer Diseases 0.000 description 2
• VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
• 241000283707 Capra Species 0.000 description 2
• 208000005590 Choroidal Neovascularization Diseases 0.000 description 2
• 206010060823 Choroidal neovascularisation Diseases 0.000 description 2
• 108091026890 Coding region Proteins 0.000 description 2
• 229920002261 Corn starch Polymers 0.000 description 2
• 102000002554 Cyclin A Human genes 0.000 description 2
• 108010068192 Cyclin A Proteins 0.000 description 2
• 102000003909 Cyclin E Human genes 0.000 description 2
• 108090000257 Cyclin E Proteins 0.000 description 2
• XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 description 2
• 101100481404 Danio rerio tie1 gene Proteins 0.000 description 2
• 206010051392 Diapedesis Diseases 0.000 description 2
• 101150048336 Flt1 gene Proteins 0.000 description 2
• 102000009465 Growth Factor Receptors Human genes 0.000 description 2
• 108010009202 Growth Factor Receptors Proteins 0.000 description 2
• 229910004373 HOAc Inorganic materials 0.000 description 2
• 208000031953 Hereditary hemorrhagic telangiectasia Diseases 0.000 description 2
• 241000238631 Hexapoda Species 0.000 description 2
• 241000282412 Homo Species 0.000 description 2
• 101000924552 Homo sapiens Angiopoietin-1 Proteins 0.000 description 2
• 108010070875 Human Immunodeficiency Virus tat Gene Products Proteins 0.000 description 2
• PMMYEEVYMWASQN-DMTCNVIQSA-N Hydroxyproline Chemical compound O[C@H]1CN[C@H](C(O)=O)C1 PMMYEEVYMWASQN-DMTCNVIQSA-N 0.000 description 2
• 208000037147 Hypercalcaemia Diseases 0.000 description 2
• 206010020751 Hypersensitivity Diseases 0.000 description 2
• 208000001953 Hypotension Diseases 0.000 description 2
• SIKJAQJRHWYJAI-UHFFFAOYSA-N Indole Chemical compound C1=CC=C2NC=CC2=C1 SIKJAQJRHWYJAI-UHFFFAOYSA-N 0.000 description 2
• 102100037850 Interferon gamma Human genes 0.000 description 2
• QNAYBMKLOCPYGJ-REOHCLBHSA-N L-alanine Chemical compound C[C@H](N)C(O)=O QNAYBMKLOCPYGJ-REOHCLBHSA-N 0.000 description 2
• KDXKERNSBIXSRK-YFKPBYRVSA-N L-lysine Chemical compound NCCCC[C@H](N)C(O)=O KDXKERNSBIXSRK-YFKPBYRVSA-N 0.000 description 2
• GDBQQVLCIARPGH-UHFFFAOYSA-N Leupeptin Natural products CC(C)CC(NC(C)=O)C(=O)NC(CC(C)C)C(=O)NC(C=O)CCCN=C(N)N GDBQQVLCIARPGH-UHFFFAOYSA-N 0.000 description 2
• KDXKERNSBIXSRK-UHFFFAOYSA-N Lysine Natural products NCCCCC(N)C(O)=O KDXKERNSBIXSRK-UHFFFAOYSA-N 0.000 description 2
• CSNNHWWHGAXBCP-UHFFFAOYSA-L Magnesium sulfate Chemical compound [Mg+2].[O-][S+2]([O-])([O-])[O-] CSNNHWWHGAXBCP-UHFFFAOYSA-L 0.000 description 2
• 101150024075 Mapk1 gene Proteins 0.000 description 2
• BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 description 2
• 102100023482 Mitogen-activated protein kinase 14 Human genes 0.000 description 2
• 241001529936 Murinae Species 0.000 description 2
• 101100481406 Mus musculus Tie1 gene Proteins 0.000 description 2
• NWIBSHFKIJFRCO-WUDYKRTCSA-N Mytomycin Chemical compound C1N2C(C(C(C)=C(N)C3=O)=O)=C3[C@@H](COC(N)=O)[C@@]2(OC)[C@@H]2[C@H]1N2 NWIBSHFKIJFRCO-WUDYKRTCSA-N 0.000 description 2
• JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical compound CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 description 2
• 108010057466 NF-kappa B Proteins 0.000 description 2
• 102000003945 NF-kappa B Human genes 0.000 description 2
• 229910052779 Neodymium Inorganic materials 0.000 description 2
• 102100028762 Neuropilin-1 Human genes 0.000 description 2
• 108090000772 Neuropilin-1 Proteins 0.000 description 2
• 208000022873 Ocular disease Diseases 0.000 description 2
• 102000016979 Other receptors Human genes 0.000 description 2
• 101150093908 PDGFRB gene Proteins 0.000 description 2
• 208000005228 Pericardial Effusion Diseases 0.000 description 2
• 208000002151 Pleural effusion Diseases 0.000 description 2
• 206010036049 Polycystic ovaries Diseases 0.000 description 2
• 102000009516 Protein Serine-Threonine Kinases Human genes 0.000 description 2
• 108010009341 Protein Serine-Threonine Kinases Proteins 0.000 description 2
• 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 2
• 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 2
• 206010037423 Pulmonary oedema Diseases 0.000 description 2
• SMWDFEZZVXVKRB-UHFFFAOYSA-N Quinoline Chemical compound N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 2
• 239000012980 RPMI-1640 medium Substances 0.000 description 2
• 206010038933 Retinopathy of prematurity Diseases 0.000 description 2
• 102000001332 SRC Human genes 0.000 description 2
• 108060006706 SRC Proteins 0.000 description 2
• 229920002684 Sepharose Polymers 0.000 description 2
• MTCFGRXMJLQNBG-UHFFFAOYSA-N Serine Natural products OCC(N)C(O)=O MTCFGRXMJLQNBG-UHFFFAOYSA-N 0.000 description 2
• QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 description 2
• 108010000499 Thromboplastin Proteins 0.000 description 2
• 102000002262 Thromboplastin Human genes 0.000 description 2
• IQFYYKKMVGJFEH-XLPZGREQSA-N Thymidine Chemical compound O=C1NC(=O)C(C)=CN1[C@@H]1O[C@H](CO)[C@@H](O)C1 IQFYYKKMVGJFEH-XLPZGREQSA-N 0.000 description 2
• GWEVSGVZZGPLCZ-UHFFFAOYSA-N Titan oxide Chemical compound O=[Ti]=O GWEVSGVZZGPLCZ-UHFFFAOYSA-N 0.000 description 2
• 108060008682 Tumor Necrosis Factor Proteins 0.000 description 2
• 102000000852 Tumor Necrosis Factor-alpha Human genes 0.000 description 2
• 108091008605 VEGF receptors Proteins 0.000 description 2
• 108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 description 2
• 108010034265 Vascular Endothelial Growth Factor Receptors Proteins 0.000 description 2
• 102100039037 Vascular endothelial growth factor A Human genes 0.000 description 2
• 208000036142 Viral infection Diseases 0.000 description 2
• 230000002159 abnormal effect Effects 0.000 description 2
• DPXJVFZANSGRMM-UHFFFAOYSA-N acetic acid;2,3,4,5,6-pentahydroxyhexanal;sodium Chemical compound [Na].CC(O)=O.OCC(O)C(O)C(O)C(O)C=O DPXJVFZANSGRMM-UHFFFAOYSA-N 0.000 description 2
• 230000002378 acidificating effect Effects 0.000 description 2
• 239000000443 aerosol Substances 0.000 description 2
• 238000001261 affinity purification Methods 0.000 description 2
• 239000000556 agonist Substances 0.000 description 2
• 235000004279 alanine Nutrition 0.000 description 2
• 208000026935 allergic disease Diseases 0.000 description 2
• 125000000539 amino acid group Chemical group 0.000 description 2
• 229940043376 ammonium acetate Drugs 0.000 description 2
• 235000019257 ammonium acetate Nutrition 0.000 description 2
• 230000006427 angiogenic response Effects 0.000 description 2
• 230000006907 apoptotic process Effects 0.000 description 2
• 239000012131 assay buffer Substances 0.000 description 2
• 208000006673 asthma Diseases 0.000 description 2
• 230000003305 autocrine Effects 0.000 description 2
• UCMIRNVEIXFBKS-UHFFFAOYSA-N beta-alanine Chemical compound NCCC(O)=O UCMIRNVEIXFBKS-UHFFFAOYSA-N 0.000 description 2
• 125000002619 bicyclic group Chemical group 0.000 description 2
• 239000011575 calcium Substances 0.000 description 2
• 208000001969 capillary hemangioma Diseases 0.000 description 2
• 235000011089 carbon dioxide Nutrition 0.000 description 2
• 239000001768 carboxy methyl cellulose Substances 0.000 description 2
• 230000003197 catalytic effect Effects 0.000 description 2
• 230000024245 cell differentiation Effects 0.000 description 2
• 230000010261 cell growth Effects 0.000 description 2
• 230000012292 cell migration Effects 0.000 description 2
• 230000036755 cellular response Effects 0.000 description 2
• 235000013339 cereals Nutrition 0.000 description 2
• OGEBRHQLRGFBNV-RZDIXWSQSA-N chembl2036808 Chemical class C12=NC(NCCCC)=NC=C2C(C=2C=CC(F)=CC=2)=NN1C[C@H]1CC[C@H](N)CC1 OGEBRHQLRGFBNV-RZDIXWSQSA-N 0.000 description 2
• RLVCBYBGVBOVFV-HZCBDIJESA-N chembl44577 Chemical compound C1CN(C)CCN1[C@@H]1CC[C@@H](N2C3=NC=NC(N)=C3C(C=3C=CC(OC=4C=CC=CC=4)=CC=3)=N2)CC1 RLVCBYBGVBOVFV-HZCBDIJESA-N 0.000 description 2
• 239000003153 chemical reaction reagent Substances 0.000 description 2
• 230000035605 chemotaxis Effects 0.000 description 2
• 238000004587 chromatography analysis Methods 0.000 description 2
• 210000000349 chromosome Anatomy 0.000 description 2
• 238000000576 coating method Methods 0.000 description 2
• 229940125904 compound 1 Drugs 0.000 description 2
• 229940125797 compound 12 Drugs 0.000 description 2
• 239000003433 contraceptive agent Substances 0.000 description 2
• 239000008120 corn starch Substances 0.000 description 2
• 239000006071 cream Substances 0.000 description 2
• 239000012043 crude product Substances 0.000 description 2
• 231100000433 cytotoxic Toxicity 0.000 description 2
• 230000001472 cytotoxic effect Effects 0.000 description 2
• 230000003111 delayed effect Effects 0.000 description 2
• 239000008121 dextrose Substances 0.000 description 2
• FLKPEMZONWLCSK-UHFFFAOYSA-N diethyl phthalate Chemical compound CCOC(=O)C1=CC=CC=C1C(=O)OCC FLKPEMZONWLCSK-UHFFFAOYSA-N 0.000 description 2
• 239000000539 dimer Substances 0.000 description 2
• 238000006471 dimerization reaction Methods 0.000 description 2
• 210000003038 endothelium Anatomy 0.000 description 2
• DNJIEGIFACGWOD-UHFFFAOYSA-N ethyl mercaptane Natural products CCS DNJIEGIFACGWOD-UHFFFAOYSA-N 0.000 description 2
• 239000013604 expression vector Substances 0.000 description 2
• 238000000605 extraction Methods 0.000 description 2
• 239000010685 fatty oil Substances 0.000 description 2
• 239000012091 fetal bovine serum Substances 0.000 description 2
• 239000000945 filler Substances 0.000 description 2
• 230000037406 food intake Effects 0.000 description 2
• BTCSSZJGUNDROE-UHFFFAOYSA-N gamma-aminobutyric acid Chemical compound NCCCC(O)=O BTCSSZJGUNDROE-UHFFFAOYSA-N 0.000 description 2
• 239000008187 granular material Substances 0.000 description 2
• 238000000227 grinding Methods 0.000 description 2
• 230000003394 haemopoietic effect Effects 0.000 description 2
• 125000005843 halogen group Chemical group 0.000 description 2
• 125000005842 heteroatom Chemical group 0.000 description 2
• 239000000833 heterodimer Substances 0.000 description 2
• 238000005734 heterodimerization reaction Methods 0.000 description 2
• 125000000487 histidyl group Chemical group [H]N([H])C(C(=O)O*)C([H])([H])C1=C([H])N([H])C([H])=N1 0.000 description 2
• 230000000148 hypercalcaemia Effects 0.000 description 2
• 208000030915 hypercalcemia disease Diseases 0.000 description 2
• 230000009610 hypersensitivity Effects 0.000 description 2
• 230000036543 hypotension Effects 0.000 description 2
• 239000005457 ice water Substances 0.000 description 2
• 239000007943 implant Substances 0.000 description 2
• 238000002513 implantation Methods 0.000 description 2
• 230000006698 induction Effects 0.000 description 2
• 230000002757 inflammatory effect Effects 0.000 description 2
• 230000004054 inflammatory process Effects 0.000 description 2
• 238000001802 infusion Methods 0.000 description 2
• 230000000977 initiatory effect Effects 0.000 description 2
• 230000004073 interleukin-2 production Effects 0.000 description 2
• QWXYZCJEXYQNEI-OSZHWHEXSA-N intermediate I Chemical compound COC(=O)[C@@]1(C=O)[C@H]2CC=[N+](C\C2=C\C)CCc2c1[nH]c1ccccc21 QWXYZCJEXYQNEI-OSZHWHEXSA-N 0.000 description 2
• 230000031146 intracellular signal transduction Effects 0.000 description 2
• 238000007918 intramuscular administration Methods 0.000 description 2
• 238000000021 kinase assay Methods 0.000 description 2
• GDBQQVLCIARPGH-ULQDDVLXSA-N leupeptin Chemical compound CC(C)C[C@H](NC(C)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@H](C=O)CCCN=C(N)N GDBQQVLCIARPGH-ULQDDVLXSA-N 0.000 description 2
• 108010052968 leupeptin Proteins 0.000 description 2
• 231100000053 low toxicity Toxicity 0.000 description 2
• 210000004072 lung Anatomy 0.000 description 2
• 210000001165 lymph node Anatomy 0.000 description 2
• 230000014759 maintenance of location Effects 0.000 description 2
• 230000003211 malignant effect Effects 0.000 description 2
• 108010082117 matrigel Proteins 0.000 description 2
• 238000005259 measurement Methods 0.000 description 2
• 230000008018 melting Effects 0.000 description 2
• 238000002844 melting Methods 0.000 description 2
• WSFSSNUMVMOOMR-BJUDXGSMSA-N methanone Chemical compound O=[11CH2] WSFSSNUMVMOOMR-BJUDXGSMSA-N 0.000 description 2
• 125000000250 methylamino group Chemical group [H]N(*)C([H])([H])[H] 0.000 description 2
• 230000005012 migration Effects 0.000 description 2
• 239000003226 mitogen Substances 0.000 description 2
• 230000002297 mitogenic effect Effects 0.000 description 2
• 230000000394 mitotic effect Effects 0.000 description 2
• 230000004048 modification Effects 0.000 description 2
• 238000012986 modification Methods 0.000 description 2
• VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical class CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 description 2
• 210000002569 neuron Anatomy 0.000 description 2
• 125000006574 non-aromatic ring group Chemical group 0.000 description 2
• 210000004940 nucleus Anatomy 0.000 description 2
• 239000010502 orange oil Substances 0.000 description 2
• 210000002997 osteoclast Anatomy 0.000 description 2
• 208000002865 osteopetrosis Diseases 0.000 description 2
• 108010068338 p38 Mitogen-Activated Protein Kinases Proteins 0.000 description 2
• 238000004806 packaging method and process Methods 0.000 description 2
• 238000007911 parenteral administration Methods 0.000 description 2
• 239000002245 particle Substances 0.000 description 2
• 230000001717 pathogenic effect Effects 0.000 description 2
• 230000001575 pathological effect Effects 0.000 description 2
• 239000008188 pellet Substances 0.000 description 2
• 230000035699 permeability Effects 0.000 description 2
• WVDDGKGOMKODPV-ZQBYOMGUSA-N phenyl(114C)methanol Chemical compound O[14CH2]C1=CC=CC=C1 WVDDGKGOMKODPV-ZQBYOMGUSA-N 0.000 description 2
• 229940080469 phosphocellulose Drugs 0.000 description 2
• XHXFXVLFKHQFAL-UHFFFAOYSA-N phosphoryl trichloride Chemical compound ClP(Cl)(Cl)=O XHXFXVLFKHQFAL-UHFFFAOYSA-N 0.000 description 2
• 229940012957 plasmin Drugs 0.000 description 2
• 229920003023 plastic Polymers 0.000 description 2
• 239000004033 plastic Substances 0.000 description 2
• 201000010065 polycystic ovary syndrome Diseases 0.000 description 2
• 239000000244 polyoxyethylene sorbitan monooleate Substances 0.000 description 2
• 235000010482 polyoxyethylene sorbitan monooleate Nutrition 0.000 description 2
• 229940068968 polysorbate 80 Drugs 0.000 description 2
• 229920000053 polysorbate 80 Polymers 0.000 description 2
• 235000011056 potassium acetate Nutrition 0.000 description 2
• 230000000770 proinflammatory effect Effects 0.000 description 2
• 208000005333 pulmonary edema Diseases 0.000 description 2
• UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 description 2
• 230000007115 recruitment Effects 0.000 description 2
• 230000006884 regulation of angiogenesis Effects 0.000 description 2
• FSYKKLYZXJSNPZ-UHFFFAOYSA-N sarcosine Chemical compound C[NH2+]CC([O-])=O FSYKKLYZXJSNPZ-UHFFFAOYSA-N 0.000 description 2
• 238000007789 sealing Methods 0.000 description 2
• 238000010898 silica gel chromatography Methods 0.000 description 2
• 210000003491 skin Anatomy 0.000 description 2
• 150000003384 small molecules Chemical class 0.000 description 2
• 235000019812 sodium carboxymethyl cellulose Nutrition 0.000 description 2
• 229920001027 sodium carboxymethylcellulose Polymers 0.000 description 2
• 239000011550 stock solution Substances 0.000 description 2
• 238000007920 subcutaneous administration Methods 0.000 description 2
• 238000007910 systemic administration Methods 0.000 description 2
• 239000000454 talc Substances 0.000 description 2
• 229910052623 talc Inorganic materials 0.000 description 2
• 235000012222 talc Nutrition 0.000 description 2
• DYHSDKLCOJIUFX-UHFFFAOYSA-N tert-butoxycarbonyl anhydride Chemical compound CC(C)(C)OC(=O)OC(=O)OC(C)(C)C DYHSDKLCOJIUFX-UHFFFAOYSA-N 0.000 description 2
• 231100001274 therapeutic index Toxicity 0.000 description 2
• 150000003557 thiazoles Chemical class 0.000 description 2
• 125000000341 threoninyl group Chemical group [H]OC([H])(C([H])([H])[H])C([H])(N([H])[H])C(*)=O 0.000 description 2
• 238000001890 transfection Methods 0.000 description 2
• 239000012096 transfection reagent Substances 0.000 description 2
• 230000009261 transgenic effect Effects 0.000 description 2
• 230000007704 transition Effects 0.000 description 2
• 230000014616 translation Effects 0.000 description 2
• 238000002054 transplantation Methods 0.000 description 2
• ONDSBJMLAHVLMI-UHFFFAOYSA-N trimethylsilyldiazomethane Chemical compound C[Si](C)(C)[CH-][N+]#N ONDSBJMLAHVLMI-UHFFFAOYSA-N 0.000 description 2
• 210000004881 tumor cell Anatomy 0.000 description 2
• 230000006459 vascular development Effects 0.000 description 2
• 230000006711 vascular endothelial growth factor production Effects 0.000 description 2
• 210000005166 vasculature Anatomy 0.000 description 2
• 239000013598 vector Substances 0.000 description 2
• 230000009385 viral infection Effects 0.000 description 2
• 239000011534 wash buffer Substances 0.000 description 2
• 230000029663 wound healing Effects 0.000 description 2
• OGNSCSPNOLGXSM-UHFFFAOYSA-N (+/-)-DABA Natural products NCCC(N)C(O)=O OGNSCSPNOLGXSM-UHFFFAOYSA-N 0.000 description 1
• AOSZTAHDEDLTLQ-AZKQZHLXSA-N (1S,2S,4R,8S,9S,11S,12R,13S,19S)-6-[(3-chlorophenyl)methyl]-12,19-difluoro-11-hydroxy-8-(2-hydroxyacetyl)-9,13-dimethyl-6-azapentacyclo[10.8.0.02,9.04,8.013,18]icosa-14,17-dien-16-one Chemical compound C([C@@H]1C[C@H]2[C@H]3[C@]([C@]4(C=CC(=O)C=C4[C@@H](F)C3)C)(F)[C@@H](O)C[C@@]2([C@@]1(C1)C(=O)CO)C)N1CC1=CC=CC(Cl)=C1 AOSZTAHDEDLTLQ-AZKQZHLXSA-N 0.000 description 1
• SZUVGFMDDVSKSI-WIFOCOSTSA-N (1s,2s,3s,5r)-1-(carboxymethyl)-3,5-bis[(4-phenoxyphenyl)methyl-propylcarbamoyl]cyclopentane-1,2-dicarboxylic acid Chemical compound O=C([C@@H]1[C@@H]([C@](CC(O)=O)([C@H](C(=O)N(CCC)CC=2C=CC(OC=3C=CC=CC=3)=CC=2)C1)C(O)=O)C(O)=O)N(CCC)CC(C=C1)=CC=C1OC1=CC=CC=C1 SZUVGFMDDVSKSI-WIFOCOSTSA-N 0.000 description 1
• LNAZSHAWQACDHT-XIYTZBAFSA-N (2r,3r,4s,5r,6s)-4,5-dimethoxy-2-(methoxymethyl)-3-[(2s,3r,4s,5r,6r)-3,4,5-trimethoxy-6-(methoxymethyl)oxan-2-yl]oxy-6-[(2r,3r,4s,5r,6r)-4,5,6-trimethoxy-2-(methoxymethyl)oxan-3-yl]oxyoxane Chemical compound CO[C@@H]1[C@@H](OC)[C@H](OC)[C@@H](COC)O[C@H]1O[C@H]1[C@H](OC)[C@@H](OC)[C@H](O[C@H]2[C@@H]([C@@H](OC)[C@H](OC)O[C@@H]2COC)OC)O[C@@H]1COC LNAZSHAWQACDHT-XIYTZBAFSA-N 0.000 description 1
• NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 description 1
• BVAUMRCGVHUWOZ-ZETCQYMHSA-N (2s)-2-(cyclohexylazaniumyl)propanoate Chemical compound OC(=O)[C@H](C)NC1CCCCC1 BVAUMRCGVHUWOZ-ZETCQYMHSA-N 0.000 description 1
• IWZSHWBGHQBIML-ZGGLMWTQSA-N (3S,8S,10R,13S,14S,17S)-17-isoquinolin-7-yl-N,N,10,13-tetramethyl-2,3,4,7,8,9,11,12,14,15,16,17-dodecahydro-1H-cyclopenta[a]phenanthren-3-amine Chemical compound CN(C)[C@H]1CC[C@]2(C)C3CC[C@@]4(C)[C@@H](CC[C@@H]4c4ccc5ccncc5c4)[C@@H]3CC=C2C1 IWZSHWBGHQBIML-ZGGLMWTQSA-N 0.000 description 1
• MZOFCQQQCNRIBI-VMXHOPILSA-N (3s)-4-[[(2s)-1-[[(2s)-1-[[(1s)-1-carboxy-2-hydroxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-5-(diaminomethylideneamino)-1-oxopentan-2-yl]amino]-3-[[2-[[(2s)-2,6-diaminohexanoyl]amino]acetyl]amino]-4-oxobutanoic acid Chemical compound OC[C@@H](C(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CCCN=C(N)N)NC(=O)[C@H](CC(O)=O)NC(=O)CNC(=O)[C@@H](N)CCCCN MZOFCQQQCNRIBI-VMXHOPILSA-N 0.000 description 1
• KEOLYBMGRQYQTN-UHFFFAOYSA-N (4-bromophenyl)-phenylmethanone Chemical compound C1=CC(Br)=CC=C1C(=O)C1=CC=CC=C1 KEOLYBMGRQYQTN-UHFFFAOYSA-N 0.000 description 1
• DDHWHFBOFISCSN-UKFGXMPHSA-N (Z)-but-2-enedioic acid 1-[1-(1-methylpiperidin-4-yl)piperidin-4-yl]-3-(4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-4-amine Chemical compound OC(=O)\C=C/C(O)=O.OC(=O)\C=C/C(O)=O.OC(=O)\C=C/C(O)=O.CN1CCC(CC1)N1CCC(CC1)n1nc(-c2ccc(Oc3ccccc3)cc2)c2c(N)ncnc12 DDHWHFBOFISCSN-UKFGXMPHSA-N 0.000 description 1
• 108091032973 (ribonucleotides)n+m Proteins 0.000 description 1
• DDMOUSALMHHKOS-UHFFFAOYSA-N 1,2-dichloro-1,1,2,2-tetrafluoroethane Chemical compound FC(F)(Cl)C(F)(F)Cl DDMOUSALMHHKOS-UHFFFAOYSA-N 0.000 description 1
• RBCUYJOFTYACGB-UHFFFAOYSA-N 1-(4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidine Chemical compound C=1C=C(N2C3=NC=NC=C3C=N2)C=CC=1OC1=CC=CC=C1 RBCUYJOFTYACGB-UHFFFAOYSA-N 0.000 description 1
• KEDOHXMZSJHFEC-UHFFFAOYSA-N 1-(oxan-4-yl)-3-(4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-4-amine Chemical compound C1=2C(N)=NC=NC=2N(C2CCOCC2)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 KEDOHXMZSJHFEC-UHFFFAOYSA-N 0.000 description 1
• GMJUPMONHWAZCP-UHFFFAOYSA-N 1-Cyclopentyl-3-(4-phenoxyphenyl)-1H-pyrazolo[3,4-d]pyrimidin-4-amine Chemical compound C1=2C(N)=NC=NC=2N(C2CCCC2)N=C1C(C=C1)=CC=C1OC1=CC=CC=C1 GMJUPMONHWAZCP-UHFFFAOYSA-N 0.000 description 1
• DFLAJSYSEJRTPH-UHFFFAOYSA-N 1-[1-(1-methylpiperidin-4-yl)piperidin-4-yl]-3-(4-phenoxyphenyl)pyrazolo[3,4-d]pyrimidin-4-amine Chemical compound C1CN(C)CCC1N1CCC(N2C3=NC=NC(N)=C3C(C=3C=CC(OC=4C=CC=CC=4)=CC=3)=N2)CC1 DFLAJSYSEJRTPH-UHFFFAOYSA-N 0.000 description 1
• ONBQEOIKXPHGMB-VBSBHUPXSA-N 1-[2-[(2s,3r,4s,5r)-3,4-dihydroxy-5-(hydroxymethyl)oxolan-2-yl]oxy-4,6-dihydroxyphenyl]-3-(4-hydroxyphenyl)propan-1-one Chemical compound O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1OC1=CC(O)=CC(O)=C1C(=O)CCC1=CC=C(O)C=C1 ONBQEOIKXPHGMB-VBSBHUPXSA-N 0.000 description 1
• BPPZXJZYCOETDA-UHFFFAOYSA-N 1-benzylpiperidin-4-ol Chemical compound C1CC(O)CCN1CC1=CC=CC=C1 BPPZXJZYCOETDA-UHFFFAOYSA-N 0.000 description 1
• IXPNQXFRVYWDDI-UHFFFAOYSA-N 1-methyl-2,4-dioxo-1,3-diazinane-5-carboximidamide Chemical compound CN1CC(C(N)=N)C(=O)NC1=O IXPNQXFRVYWDDI-UHFFFAOYSA-N 0.000 description 1
• HUUPVABNAQUEJW-UHFFFAOYSA-N 1-methylpiperidin-4-one Chemical compound CN1CCC(=O)CC1 HUUPVABNAQUEJW-UHFFFAOYSA-N 0.000 description 1
• CCDBCHAQIXKJCG-UHFFFAOYSA-N 1-propan-2-ylpiperidin-4-one Chemical compound CC(C)N1CCC(=O)CC1 CCDBCHAQIXKJCG-UHFFFAOYSA-N 0.000 description 1
• VOXZDWNPVJITMN-UHFFFAOYSA-N 13-methyl-6,7,8,9,11,12,14,15,16,17-decahydrocyclopenta[a]phenanthrene-3,17-diol Chemical compound OC1=CC=C2C3CCC(C)(C(CC4)O)C4C3CCC2=C1 VOXZDWNPVJITMN-UHFFFAOYSA-N 0.000 description 1
• VOXZDWNPVJITMN-ZBRFXRBCSA-N 17β-estradiol Chemical compound OC1=CC=C2[C@H]3CC[C@](C)([C@H](CC4)O)[C@@H]4[C@@H]3CCC2=C1 VOXZDWNPVJITMN-ZBRFXRBCSA-N 0.000 description 1
• KJUGUADJHNHALS-UHFFFAOYSA-N 1H-tetrazole Substances C=1N=NNN=1 KJUGUADJHNHALS-UHFFFAOYSA-N 0.000 description 1
• QUKPALAWEPMWOS-UHFFFAOYSA-N 1h-pyrazolo[3,4-d]pyrimidine Chemical compound C1=NC=C2C=NNC2=N1 QUKPALAWEPMWOS-UHFFFAOYSA-N 0.000 description 1
• FRUWMYWEARDNTC-UHFFFAOYSA-N 2,3,3a,4-tetrahydro-1h-indole Chemical compound C1C=CC=C2NCCC21 FRUWMYWEARDNTC-UHFFFAOYSA-N 0.000 description 1
• TXHAHOVNFDVCCC-UHFFFAOYSA-N 2-(tert-butylazaniumyl)acetate Chemical compound CC(C)(C)NCC(O)=O TXHAHOVNFDVCCC-UHFFFAOYSA-N 0.000 description 1
• QWCKQJZIFLGMSD-UHFFFAOYSA-N 2-Aminobutanoic acid Natural products CCC(N)C(O)=O QWCKQJZIFLGMSD-UHFFFAOYSA-N 0.000 description 1
• NGNBDVOYPDDBFK-UHFFFAOYSA-N 2-[2,4-di(pentan-2-yl)phenoxy]acetyl chloride Chemical compound CCCC(C)C1=CC=C(OCC(Cl)=O)C(C(C)CCC)=C1 NGNBDVOYPDDBFK-UHFFFAOYSA-N 0.000 description 1
• UHQFXIWMAQOCAN-UHFFFAOYSA-N 2-amino-1,3-dihydroindene-2-carboxylic acid Chemical compound C1=CC=C2CC(N)(C(O)=O)CC2=C1 UHQFXIWMAQOCAN-UHFFFAOYSA-N 0.000 description 1
• FZZMTSNZRBFGGU-UHFFFAOYSA-N 2-chloro-7-fluoroquinazolin-4-amine Chemical compound FC1=CC=C2C(N)=NC(Cl)=NC2=C1 FZZMTSNZRBFGGU-UHFFFAOYSA-N 0.000 description 1
• HZLCGUXUOFWCCN-UHFFFAOYSA-N 2-hydroxynonadecane-1,2,3-tricarboxylic acid Chemical compound CCCCCCCCCCCCCCCCC(C(O)=O)C(O)(C(O)=O)CC(O)=O HZLCGUXUOFWCCN-UHFFFAOYSA-N 0.000 description 1
• WIQRSJOCVVPMPS-UHFFFAOYSA-N 3-(1h-indol-2-yl)pyrrole-2,5-dione Chemical class O=C1NC(=O)C(C=2NC3=CC=CC=C3C=2)=C1 WIQRSJOCVVPMPS-UHFFFAOYSA-N 0.000 description 1
• NUFBIAUZAMHTSP-UHFFFAOYSA-N 3-(n-morpholino)-2-hydroxypropanesulfonic acid Chemical compound OS(=O)(=O)CC(O)CN1CCOCC1 NUFBIAUZAMHTSP-UHFFFAOYSA-N 0.000 description 1
• AQTFKGDWFRRIHR-UHFFFAOYSA-L 3-[18-(2-carboxylatoethyl)-8,13-bis(ethenyl)-3,7,12,17-tetramethylporphyrin-21,24-diid-2-yl]propanoate;cobalt(2+);hydron Chemical compound [Co+2].[N-]1C(C=C2C(=C(C)C(C=C3C(=C(C)C(=C4)[N-]3)C=C)=N2)C=C)=C(C)C(CCC(O)=O)=C1C=C1C(CCC(O)=O)=C(C)C4=N1 AQTFKGDWFRRIHR-UHFFFAOYSA-L 0.000 description 1
• WEVYNIUIFUYDGI-UHFFFAOYSA-N 3-[6-[4-(trifluoromethoxy)anilino]-4-pyrimidinyl]benzamide Chemical compound NC(=O)C1=CC=CC(C=2N=CN=C(NC=3C=CC(OC(F)(F)F)=CC=3)C=2)=C1 WEVYNIUIFUYDGI-UHFFFAOYSA-N 0.000 description 1
• NANPEAQRYIILSP-UHFFFAOYSA-N 3-iodo-1-[4-(4-methylpiperazin-1-yl)cyclohexyl]pyrazolo[3,4-d]pyrimidin-4-amine Chemical compound C1CN(C)CCN1C1CCC(N2C3=NC=NC(N)=C3C(I)=N2)CC1 NANPEAQRYIILSP-UHFFFAOYSA-N 0.000 description 1
• HQAIUXZORKJOJY-UHFFFAOYSA-N 3-iodo-2h-pyrazolo[3,4-d]pyrimidin-4-amine Chemical compound NC1=NC=NC2=NNC(I)=C12 HQAIUXZORKJOJY-UHFFFAOYSA-N 0.000 description 1
• CMUHFUGDYMFHEI-QMMMGPOBSA-N 4-amino-L-phenylalanine Chemical compound OC(=O)[C@@H](N)CC1=CC=C(N)C=C1 CMUHFUGDYMFHEI-QMMMGPOBSA-N 0.000 description 1
• GAMYYCRTACQSBR-UHFFFAOYSA-N 4-azabenzimidazole Chemical compound C1=CC=C2NC=NC2=N1 GAMYYCRTACQSBR-UHFFFAOYSA-N 0.000 description 1
• GZRMNMGWNKSANY-UHFFFAOYSA-N 4-bromo-2-fluoroaniline Chemical compound NC1=CC=C(Br)C=C1F GZRMNMGWNKSANY-UHFFFAOYSA-N 0.000 description 1
• JDUYPUMQALQRCN-UHFFFAOYSA-N 4-bromophenyl phenyl ether Chemical compound C1=CC(Br)=CC=C1OC1=CC=CC=C1 JDUYPUMQALQRCN-UHFFFAOYSA-N 0.000 description 1
• RYAQFHLUEMJOMF-UHFFFAOYSA-N 4-phenoxybenzoic acid Chemical compound C1=CC(C(=O)O)=CC=C1OC1=CC=CC=C1 RYAQFHLUEMJOMF-UHFFFAOYSA-N 0.000 description 1
• FFNKBQRKZRMYCL-UHFFFAOYSA-N 5-amino-1h-pyrazole-4-carbonitrile Chemical compound NC1=NNC=C1C#N FFNKBQRKZRMYCL-UHFFFAOYSA-N 0.000 description 1
• JJTNLWSCFYERCK-UHFFFAOYSA-N 7h-pyrrolo[2,3-d]pyrimidine Chemical compound N1=CN=C2NC=CC2=C1 JJTNLWSCFYERCK-UHFFFAOYSA-N 0.000 description 1
• 208000030507 AIDS Diseases 0.000 description 1
• 244000215068 Acacia senegal Species 0.000 description 1
• 208000030090 Acute Disease Diseases 0.000 description 1
• 229920001817 Agar Polymers 0.000 description 1
• 206010002198 Anaphylactic reaction Diseases 0.000 description 1
• 108010048154 Angiopoietin-1 Proteins 0.000 description 1
• 108010048036 Angiopoietin-2 Proteins 0.000 description 1
• 201000002909 Aspergillosis Diseases 0.000 description 1
• 241000228212 Aspergillus Species 0.000 description 1
• 208000036641 Aspergillus infections Diseases 0.000 description 1
• 241000416162 Astragalus gummifer Species 0.000 description 1
• 208000032116 Autoimmune Experimental Encephalomyelitis Diseases 0.000 description 1
• 231100000699 Bacterial toxin Toxicity 0.000 description 1
• 208000023328 Basedow disease Diseases 0.000 description 1
• OGBVRMYSNSKIEF-UHFFFAOYSA-N Benzylphosphonic acid Chemical class OP(O)(=O)CC1=CC=CC=C1 OGBVRMYSNSKIEF-UHFFFAOYSA-N 0.000 description 1
• DWRXFEITVBNRMK-UHFFFAOYSA-N Beta-D-1-Arabinofuranosylthymine Natural products O=C1NC(=O)C(C)=CN1C1C(O)C(O)C(CO)O1 DWRXFEITVBNRMK-UHFFFAOYSA-N 0.000 description 1
• 102000004506 Blood Proteins Human genes 0.000 description 1
• 108010017384 Blood Proteins Proteins 0.000 description 1
• 208000006386 Bone Resorption Diseases 0.000 description 1
• 208000020084 Bone disease Diseases 0.000 description 1
• WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
• COVZYZSDYWQREU-UHFFFAOYSA-N Busulfan Chemical compound CS(=O)(=O)OCCCCOS(C)(=O)=O COVZYZSDYWQREU-UHFFFAOYSA-N 0.000 description 1
• RLVCBYBGVBOVFV-SZPZYZBQSA-N C1CN(C)CCN1[C@@H]1CC[C@H](N2C3=NC=NC(N)=C3C(C=3C=CC(OC=4C=CC=CC=4)=CC=3)=N2)CC1 Chemical compound C1CN(C)CCN1[C@@H]1CC[C@H](N2C3=NC=NC(N)=C3C(C=3C=CC(OC=4C=CC=CC=4)=CC=3)=N2)CC1 RLVCBYBGVBOVFV-SZPZYZBQSA-N 0.000 description 1
• 101150047144 CDC28 gene Proteins 0.000 description 1
• 101100516563 Caenorhabditis elegans nhr-6 gene Proteins 0.000 description 1
• 102000016289 Cell Adhesion Molecules Human genes 0.000 description 1
• 108010067225 Cell Adhesion Molecules Proteins 0.000 description 1
• 229920000623 Cellulose acetate phthalate Polymers 0.000 description 1
• 102000019034 Chemokines Human genes 0.000 description 1
• 108010012236 Chemokines Proteins 0.000 description 1
• 102000000503 Collagen Type II Human genes 0.000 description 1
• 108010041390 Collagen Type II Proteins 0.000 description 1
• 241000694440 Colpidium aqueous Species 0.000 description 1
• 208000035473 Communicable disease Diseases 0.000 description 1
• 229940126657 Compound 17 Drugs 0.000 description 1
• 101150069913 Csk gene Proteins 0.000 description 1
• 102000003910 Cyclin D Human genes 0.000 description 1
• 108090000259 Cyclin D Proteins 0.000 description 1
• 108010025464 Cyclin-Dependent Kinase 4 Proteins 0.000 description 1
• 108010025454 Cyclin-Dependent Kinase 5 Proteins 0.000 description 1
• 102100032857 Cyclin-dependent kinase 1 Human genes 0.000 description 1
• 101710106279 Cyclin-dependent kinase 1 Proteins 0.000 description 1
• 102100036252 Cyclin-dependent kinase 4 Human genes 0.000 description 1
• 102100026805 Cyclin-dependent-like kinase 5 Human genes 0.000 description 1
• OABOXRPGTFRBFZ-IMJSIDKUSA-N Cys-Cys Chemical compound SC[C@H](N)C(=O)N[C@@H](CS)C(O)=O OABOXRPGTFRBFZ-IMJSIDKUSA-N 0.000 description 1
• FBPFZTCFMRRESA-KVTDHHQDSA-N D-Mannitol Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@H](O)CO FBPFZTCFMRRESA-KVTDHHQDSA-N 0.000 description 1
• QWCKQJZIFLGMSD-GSVOUGTGSA-N D-alpha-aminobutyric acid Chemical compound CC[C@@H](N)C(O)=O QWCKQJZIFLGMSD-GSVOUGTGSA-N 0.000 description 1
• 108020004414 DNA Proteins 0.000 description 1
• 230000006820 DNA synthesis Effects 0.000 description 1
• 101100503636 Danio rerio fyna gene Proteins 0.000 description 1
• 206010012289 Dementia Diseases 0.000 description 1
• 229920002307 Dextran Polymers 0.000 description 1
• 208000002249 Diabetes Complications Diseases 0.000 description 1
• 206010012655 Diabetic complications Diseases 0.000 description 1
• 239000004338 Dichlorodifluoromethane Substances 0.000 description 1
• BWGNESOTFCXPMA-UHFFFAOYSA-N Dihydrogen disulfide Chemical compound SS BWGNESOTFCXPMA-UHFFFAOYSA-N 0.000 description 1
• 101000827763 Drosophila melanogaster Fibroblast growth factor receptor homolog 1 Proteins 0.000 description 1
• KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 1
• 108060006698 EGF receptor Proteins 0.000 description 1
• LVGKNOAMLMIIKO-UHFFFAOYSA-N Elaidinsaeure-aethylester Natural products CCCCCCCCC=CCCCCCCCC(=O)OCC LVGKNOAMLMIIKO-UHFFFAOYSA-N 0.000 description 1
• 241000792859 Enema Species 0.000 description 1
• 241000400611 Eucalyptus deanei Species 0.000 description 1
• 208000006168 Ewing Sarcoma Diseases 0.000 description 1
• 108010037362 Extracellular Matrix Proteins Proteins 0.000 description 1
• 102000010834 Extracellular Matrix Proteins Human genes 0.000 description 1
• 101150018272 FYN gene Proteins 0.000 description 1
• RRSNDVCODIMOFX-MPKOGUQCSA-N Fc1c(Cl)cccc1[C@H]1[C@@H](NC2(CCCCC2)[C@@]11C(=O)Nc2cc(Cl)ccc12)C(=O)Nc1ccc(cc1)C(=O)NCCCCCc1cccc2C(=O)N(Cc12)C1CCC(=O)NC1=O Chemical compound Fc1c(Cl)cccc1[C@H]1[C@@H](NC2(CCCCC2)[C@@]11C(=O)Nc2cc(Cl)ccc12)C(=O)Nc1ccc(cc1)C(=O)NCCCCCc1cccc2C(=O)N(Cc12)C1CCC(=O)NC1=O RRSNDVCODIMOFX-MPKOGUQCSA-N 0.000 description 1
• 241000282324 Felis Species 0.000 description 1
• 102000009123 Fibrin Human genes 0.000 description 1
• 108010073385 Fibrin Proteins 0.000 description 1
• BWGVNKXGVNDBDI-UHFFFAOYSA-N Fibrin monomer Chemical compound CNC(=O)CNC(=O)CN BWGVNKXGVNDBDI-UHFFFAOYSA-N 0.000 description 1
• 102000044168 Fibroblast Growth Factor Receptor Human genes 0.000 description 1
• 102100024785 Fibroblast growth factor 2 Human genes 0.000 description 1
• KRHYYFGTRYWZRS-UHFFFAOYSA-M Fluoride anion Chemical compound [F-] KRHYYFGTRYWZRS-UHFFFAOYSA-M 0.000 description 1
• 102000001267 GSK3 Human genes 0.000 description 1
• 108060006662 GSK3 Proteins 0.000 description 1
• 102000002254 Glycogen Synthase Kinase 3 Human genes 0.000 description 1
• 108010014905 Glycogen Synthase Kinase 3 Proteins 0.000 description 1
• 102000006771 Gonadotropins Human genes 0.000 description 1
• 108010086677 Gonadotropins Proteins 0.000 description 1
• 208000015023 Graves' disease Diseases 0.000 description 1
• 229920000084 Gum arabic Polymers 0.000 description 1
• 241000557766 Guthriea Species 0.000 description 1
• 241000589989 Helicobacter Species 0.000 description 1
• 102000001554 Hemoglobins Human genes 0.000 description 1
• 108010054147 Hemoglobins Proteins 0.000 description 1
• 208000032843 Hemorrhage Diseases 0.000 description 1
• 108010033040 Histones Proteins 0.000 description 1
• 101001005128 Homo sapiens LIM domain kinase 1 Proteins 0.000 description 1
• 101000979342 Homo sapiens Nuclear factor NF-kappa-B p105 subunit Proteins 0.000 description 1
• 101001001487 Homo sapiens Phosphatidylinositol-glycan biosynthesis class F protein Proteins 0.000 description 1
• 101001092185 Homo sapiens Regulator of cell cycle RGCC Proteins 0.000 description 1
• 101000742596 Homo sapiens Vascular endothelial growth factor C Proteins 0.000 description 1
• 241000725303 Human immunodeficiency virus Species 0.000 description 1
• 241000701806 Human papillomavirus Species 0.000 description 1
• CPELXLSAUQHCOX-UHFFFAOYSA-N Hydrogen bromide Chemical class Br CPELXLSAUQHCOX-UHFFFAOYSA-N 0.000 description 1
• 102000038455 IGF Type 1 Receptor Human genes 0.000 description 1
• DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
• 206010061598 Immunodeficiency Diseases 0.000 description 1
• 206010061218 Inflammation Diseases 0.000 description 1
• 102000008070 Interferon-gamma Human genes 0.000 description 1
• 108010002352 Interleukin-1 Proteins 0.000 description 1
• 102100036342 Interleukin-1 receptor-associated kinase 1 Human genes 0.000 description 1
• 101710199015 Interleukin-1 receptor-associated kinase 1 Proteins 0.000 description 1
• 102100036433 Interleukin-1 receptor-associated kinase-like 2 Human genes 0.000 description 1
• 101710182491 Interleukin-1 receptor-associated kinase-like 2 Proteins 0.000 description 1
• 108010024121 Janus Kinases Proteins 0.000 description 1
• 102000015617 Janus Kinases Human genes 0.000 description 1
• 208000002260 Keloid Diseases 0.000 description 1
• 206010023330 Keloid scar Diseases 0.000 description 1
• AHLPHDHHMVZTML-BYPYZUCNSA-N L-Ornithine Chemical compound NCCC[C@H](N)C(O)=O AHLPHDHHMVZTML-BYPYZUCNSA-N 0.000 description 1
• LRQKBLKVPFOOQJ-YFKPBYRVSA-N L-norleucine Chemical compound CCCC[C@H]([NH3+])C([O-])=O LRQKBLKVPFOOQJ-YFKPBYRVSA-N 0.000 description 1
• 102100026023 LIM domain kinase 1 Human genes 0.000 description 1
• 208000004852 Lung Injury Diseases 0.000 description 1
• 108010002481 Lymphocyte Specific Protein Tyrosine Kinase p56(lck) Proteins 0.000 description 1
• 102000036243 Lymphocyte Specific Protein Tyrosine Kinase p56(lck) Human genes 0.000 description 1
• 101150058160 Lyn gene Proteins 0.000 description 1
• 239000004472 Lysine Substances 0.000 description 1
• 108091054455 MAP kinase family Proteins 0.000 description 1
• 102000043136 MAP kinase family Human genes 0.000 description 1
• 102100028198 Macrophage colony-stimulating factor 1 receptor Human genes 0.000 description 1
• 101710150918 Macrophage colony-stimulating factor 1 receptor Proteins 0.000 description 1
• 229930195725 Mannitol Natural products 0.000 description 1
• 102000007474 Multiprotein Complexes Human genes 0.000 description 1
• 101100323232 Mus musculus Ang3 gene Proteins 0.000 description 1
• 101100216078 Mus musculus Ang4 gene Proteins 0.000 description 1
• 101100381649 Mus musculus Bik gene Proteins 0.000 description 1
• 101100381845 Mus musculus Blk gene Proteins 0.000 description 1
• 101100268066 Mus musculus Zap70 gene Proteins 0.000 description 1
• 102000047918 Myelin Basic Human genes 0.000 description 1
• 102000006386 Myelin Proteins Human genes 0.000 description 1
• 108010083674 Myelin Proteins Proteins 0.000 description 1
• 101710107068 Myelin basic protein Proteins 0.000 description 1
• HSHXDCVZWHOWCS-UHFFFAOYSA-N N'-hexadecylthiophene-2-carbohydrazide Chemical compound CCCCCCCCCCCCCCCCNNC(=O)c1cccs1 HSHXDCVZWHOWCS-UHFFFAOYSA-N 0.000 description 1
• GDFAOVXKHJXLEI-VKHMYHEASA-N N-methyl-L-alanine Chemical compound C[NH2+][C@@H](C)C([O-])=O GDFAOVXKHJXLEI-VKHMYHEASA-N 0.000 description 1
• XLBVNMSMFQMKEY-BYPYZUCNSA-N N-methyl-L-glutamic acid Chemical compound CN[C@H](C(O)=O)CCC(O)=O XLBVNMSMFQMKEY-BYPYZUCNSA-N 0.000 description 1
• 108010014632 NF-kappa B kinase Proteins 0.000 description 1
• 102000019148 NF-kappaB-inducing kinase activity proteins Human genes 0.000 description 1
• 108040008091 NF-kappaB-inducing kinase activity proteins Proteins 0.000 description 1
• 206010061309 Neoplasm progression Diseases 0.000 description 1
• 239000000020 Nitrocellulose Substances 0.000 description 1
• 102100023050 Nuclear factor NF-kappa-B p105 subunit Human genes 0.000 description 1
• 235000019502 Orange oil Nutrition 0.000 description 1
• AHLPHDHHMVZTML-UHFFFAOYSA-N Orn-delta-NH2 Natural products NCCCC(N)C(O)=O AHLPHDHHMVZTML-UHFFFAOYSA-N 0.000 description 1
• UTJLXEIPEHZYQJ-UHFFFAOYSA-N Ornithine Natural products OC(=O)C(C)CCCN UTJLXEIPEHZYQJ-UHFFFAOYSA-N 0.000 description 1
• 206010033128 Ovarian cancer Diseases 0.000 description 1
• 206010061535 Ovarian neoplasm Diseases 0.000 description 1
• 108091008606 PDGF receptors Proteins 0.000 description 1
• 229910019142 PO4 Inorganic materials 0.000 description 1
• 206010061902 Pancreatic neoplasm Diseases 0.000 description 1
• 208000034038 Pathologic Neovascularization Diseases 0.000 description 1
• 241001494479 Pecora Species 0.000 description 1
• 208000008469 Peptic Ulcer Diseases 0.000 description 1
• 201000005702 Pertussis Diseases 0.000 description 1
• 102000004160 Phosphoric Monoester Hydrolases Human genes 0.000 description 1
• 108090000608 Phosphoric Monoester Hydrolases Proteins 0.000 description 1
• 102000011653 Platelet-Derived Growth Factor Receptors Human genes 0.000 description 1
• 208000037062 Polyps Diseases 0.000 description 1
• 229920001213 Polysorbate 20 Polymers 0.000 description 1
• 229920002642 Polysorbate 65 Polymers 0.000 description 1
• ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
• 208000000236 Prostatic Neoplasms Diseases 0.000 description 1
• 108700020978 Proto-Oncogene Proteins 0.000 description 1
• 102000052575 Proto-Oncogene Human genes 0.000 description 1
• 108010071563 Proto-Oncogene Proteins c-fos Proteins 0.000 description 1
• 102000007568 Proto-Oncogene Proteins c-fos Human genes 0.000 description 1
• WTKZEGDFNFYCGP-UHFFFAOYSA-N Pyrazole Chemical compound C=1C=NNC=1 WTKZEGDFNFYCGP-UHFFFAOYSA-N 0.000 description 1
• 206010037660 Pyrexia Diseases 0.000 description 1
• 101710141955 RAF proto-oncogene serine/threonine-protein kinase Proteins 0.000 description 1
• 102100033479 RAF proto-oncogene serine/threonine-protein kinase Human genes 0.000 description 1
• 239000012083 RIPA buffer Substances 0.000 description 1
• 102100022419 RPA-interacting protein Human genes 0.000 description 1
• 229940078123 Ras inhibitor Drugs 0.000 description 1
• 101000851003 Rattus norvegicus Vascular endothelial growth factor receptor 2 Proteins 0.000 description 1
• 229940127361 Receptor Tyrosine Kinase Inhibitors Drugs 0.000 description 1
• 108091005682 Receptor kinases Proteins 0.000 description 1
• 208000015634 Rectal Neoplasms Diseases 0.000 description 1
• 102100035542 Regulator of cell cycle RGCC Human genes 0.000 description 1
• 108090000829 Ribosome Inactivating Proteins Proteins 0.000 description 1
• 241000283984 Rodentia Species 0.000 description 1
• 241000220317 Rosa Species 0.000 description 1
• 108091008118 SFKs Proteins 0.000 description 1
• 102000038012 SFKs Human genes 0.000 description 1
• 102000014400 SH2 domains Human genes 0.000 description 1
• 108050003452 SH2 domains Proteins 0.000 description 1
• 108010077895 Sarcosine Proteins 0.000 description 1
• 241000239226 Scorpiones Species 0.000 description 1
• 229940124639 Selective inhibitor Drugs 0.000 description 1
• 206010040070 Septic Shock Diseases 0.000 description 1
• 108010071390 Serum Albumin Proteins 0.000 description 1
• 102000007562 Serum Albumin Human genes 0.000 description 1
• 229920001800 Shellac Polymers 0.000 description 1
• 229920002125 Sokalan® Polymers 0.000 description 1
• 240000006394 Sorghum bicolor Species 0.000 description 1
• 208000027073 Stargardt disease Diseases 0.000 description 1
• 208000005718 Stomach Neoplasms Diseases 0.000 description 1
• 101710172711 Structural protein Proteins 0.000 description 1
• 229930006000 Sucrose Natural products 0.000 description 1
• CZMRCDWAGMRECN-UGDNZRGBSA-N Sucrose Chemical compound O[C@H]1[C@H](O)[C@@H](CO)O[C@@]1(CO)O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 CZMRCDWAGMRECN-UGDNZRGBSA-N 0.000 description 1
• NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 description 1
• 108010016672 Syk Kinase Proteins 0.000 description 1
• 102000000551 Syk Kinase Human genes 0.000 description 1
• 108091008874 T cell receptors Proteins 0.000 description 1
• 102000016266 T-Cell Antigen Receptors Human genes 0.000 description 1
• 108010090091 TIE-2 Receptor Proteins 0.000 description 1
• 102000012753 TIE-2 Receptor Human genes 0.000 description 1
• 108010009978 Tec protein-tyrosine kinase Proteins 0.000 description 1
• 108090000190 Thrombin Proteins 0.000 description 1
• 229920001615 Tragacanth Polymers 0.000 description 1
• 102100040247 Tumor necrosis factor Human genes 0.000 description 1
• 208000007097 Urinary Bladder Neoplasms Diseases 0.000 description 1
• 208000021017 Weight Gain Diseases 0.000 description 1
• LNUFLCYMSVYYNW-ZPJMAFJPSA-N [(2r,3r,4s,5r,6r)-2-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[(2r,3r,4s,5r,6r)-6-[[(3s,5s,8r,9s,10s,13r,14s,17r)-10,13-dimethyl-17-[(2r)-6-methylheptan-2-yl]-2,3,4,5,6,7,8,9,11,12,14,15,16,17-tetradecahydro-1h-cyclopenta[a]phenanthren-3-yl]oxy]-4,5-disulfo Chemical compound O([C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1[C@@H](COS(O)(=O)=O)O[C@H]([C@@H]([C@H]1OS(O)(=O)=O)OS(O)(=O)=O)O[C@@H]1C[C@@H]2CC[C@H]3[C@@H]4CC[C@@H]([C@]4(CC[C@@H]3[C@@]2(C)CC1)C)[C@H](C)CCCC(C)C)[C@H]1O[C@H](COS(O)(=O)=O)[C@@H](OS(O)(=O)=O)[C@H](OS(O)(=O)=O)[C@H]1OS(O)(=O)=O LNUFLCYMSVYYNW-ZPJMAFJPSA-N 0.000 description 1
• KPCZJLGGXRGYIE-UHFFFAOYSA-N [C]1=CC=CN=C1 Chemical group [C]1=CC=CN=C1 KPCZJLGGXRGYIE-UHFFFAOYSA-N 0.000 description 1
• 108700025690 abl Genes Proteins 0.000 description 1
• 235000010489 acacia gum Nutrition 0.000 description 1
• 239000000205 acacia gum Substances 0.000 description 1
• 150000001242 acetic acid derivatives Chemical class 0.000 description 1
• 230000003213 activating effect Effects 0.000 description 1
• 239000002671 adjuvant Substances 0.000 description 1
• 239000008272 agar Substances 0.000 description 1
• 235000010419 agar Nutrition 0.000 description 1
• 229940040563 agaric acid Drugs 0.000 description 1
• 238000007605 air drying Methods 0.000 description 1
• 235000010443 alginic acid Nutrition 0.000 description 1
• 229920000615 alginic acid Polymers 0.000 description 1
• 239000000783 alginic acid Substances 0.000 description 1
• 229960001126 alginic acid Drugs 0.000 description 1
• 150000004781 alginic acids Chemical class 0.000 description 1
• 230000009285 allergic inflammation Effects 0.000 description 1
• 230000000735 allogeneic effect Effects 0.000 description 1
• OFCNXPDARWKPPY-UHFFFAOYSA-N allopurinol Chemical compound OC1=NC=NC2=C1C=NN2 OFCNXPDARWKPPY-UHFFFAOYSA-N 0.000 description 1
• 229910021529 ammonia Inorganic materials 0.000 description 1
• VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 1
• 230000036783 anaphylactic response Effects 0.000 description 1
• 208000003455 anaphylaxis Diseases 0.000 description 1
• 230000003466 anti-cipated effect Effects 0.000 description 1
• 230000003501 anti-edematous effect Effects 0.000 description 1
• 230000003110 anti-inflammatory effect Effects 0.000 description 1
• 230000001028 anti-proliverative effect Effects 0.000 description 1
• 230000000890 antigenic effect Effects 0.000 description 1
• 239000000739 antihistaminic agent Substances 0.000 description 1
• 229940125715 antihistaminic agent Drugs 0.000 description 1
• 230000001640 apoptogenic effect Effects 0.000 description 1
• 239000008346 aqueous phase Substances 0.000 description 1
• 239000008135 aqueous vehicle Substances 0.000 description 1
• 150000001483 arginine derivatives Chemical class 0.000 description 1
• 230000002917 arthritic effect Effects 0.000 description 1
• 238000011914 asymmetric synthesis Methods 0.000 description 1
• 239000012298 atmosphere Substances 0.000 description 1
• 125000004429 atom Chemical group 0.000 description 1
• QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 description 1
• 239000012752 auxiliary agent Substances 0.000 description 1
• 210000003719 b-lymphocyte Anatomy 0.000 description 1
• 239000000688 bacterial toxin Substances 0.000 description 1
• 230000004888 barrier function Effects 0.000 description 1
• 239000007640 basal medium Substances 0.000 description 1
• 230000008901 benefit Effects 0.000 description 1
• 150000001558 benzoic acid derivatives Chemical class 0.000 description 1
• 125000005874 benzothiadiazolyl group Chemical group 0.000 description 1
• IQFYYKKMVGJFEH-UHFFFAOYSA-N beta-L-thymidine Natural products O=C1NC(=O)C(C)=CN1C1OC(CO)C(O)C1 IQFYYKKMVGJFEH-UHFFFAOYSA-N 0.000 description 1
• 229940000635 beta-alanine Drugs 0.000 description 1
• 239000011230 binding agent Substances 0.000 description 1
• 238000004166 bioassay Methods 0.000 description 1
• 229920000249 biocompatible polymer Polymers 0.000 description 1
• 230000005540 biological transmission Effects 0.000 description 1
• 230000002051 biphasic effect Effects 0.000 description 1
• 210000001109 blastomere Anatomy 0.000 description 1
• 230000000740 bleeding effect Effects 0.000 description 1
• 210000004369 blood Anatomy 0.000 description 1
• 239000008280 blood Substances 0.000 description 1
• 210000001185 bone marrow Anatomy 0.000 description 1
• 230000024279 bone resorption Effects 0.000 description 1
• 210000000481 breast Anatomy 0.000 description 1
• GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
• BRTFVKHPEHKBQF-UHFFFAOYSA-N bromocyclopentane Chemical compound BrC1CCCC1 BRTFVKHPEHKBQF-UHFFFAOYSA-N 0.000 description 1
• 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
• 125000004744 butyloxycarbonyl group Chemical group 0.000 description 1
• 229910000019 calcium carbonate Inorganic materials 0.000 description 1
• 239000001506 calcium phosphate Substances 0.000 description 1
• 229910000389 calcium phosphate Inorganic materials 0.000 description 1
• 235000011010 calcium phosphates Nutrition 0.000 description 1
• 230000009702 cancer cell proliferation Effects 0.000 description 1
• 239000001569 carbon dioxide Substances 0.000 description 1
• 229910002092 carbon dioxide Inorganic materials 0.000 description 1
• 229960004424 carbon dioxide Drugs 0.000 description 1
• 125000006297 carbonyl amino group Chemical group [H]N([*:2])C([*:1])=O 0.000 description 1
• 230000000747 cardiac effect Effects 0.000 description 1
• 230000002612 cardiopulmonary effect Effects 0.000 description 1
• 208000003295 carpal tunnel syndrome Diseases 0.000 description 1
• 239000003054 catalyst Substances 0.000 description 1
• 230000020411 cell activation Effects 0.000 description 1
• 230000021164 cell adhesion Effects 0.000 description 1
• 238000000423 cell based assay Methods 0.000 description 1
• 230000030833 cell death Effects 0.000 description 1
• 230000032823 cell division Effects 0.000 description 1
• 230000003915 cell function Effects 0.000 description 1
• 239000013592 cell lysate Substances 0.000 description 1
• 210000000170 cell membrane Anatomy 0.000 description 1
• 230000019522 cellular metabolic process Effects 0.000 description 1
• 230000005754 cellular signaling Effects 0.000 description 1
• 229920002678 cellulose Chemical class 0.000 description 1
• 239000001913 cellulose Chemical class 0.000 description 1
• 235000010980 cellulose Nutrition 0.000 description 1
• 229940081734 cellulose acetate phthalate Drugs 0.000 description 1
• 208000013557 cerebral hemisphere cancer Diseases 0.000 description 1
• 201000008860 cerebrum cancer Diseases 0.000 description 1
• 210000003679 cervix uteri Anatomy 0.000 description 1
• 150000005829 chemical entities Chemical class 0.000 description 1
• 239000007795 chemical reaction product Substances 0.000 description 1
• 150000001860 citric acid derivatives Chemical class 0.000 description 1
• 229940110456 cocoa butter Drugs 0.000 description 1
• 235000019868 cocoa butter Nutrition 0.000 description 1
• 210000001072 colon Anatomy 0.000 description 1
• 208000029742 colonic neoplasm Diseases 0.000 description 1
• 229940126543 compound 14 Drugs 0.000 description 1
• 229940126142 compound 16 Drugs 0.000 description 1
• 229940126214 compound 3 Drugs 0.000 description 1
• 229940125898 compound 5 Drugs 0.000 description 1
• 210000002808 connective tissue Anatomy 0.000 description 1
• 238000010276 construction Methods 0.000 description 1
• 229940124558 contraceptive agent Drugs 0.000 description 1
• 229920001577 copolymer Polymers 0.000 description 1
• 229940099112 cornstarch Drugs 0.000 description 1
• 229940111134 coxibs Drugs 0.000 description 1
• 239000010779 crude oil Substances 0.000 description 1
• 239000012228 culture supernatant Substances 0.000 description 1
• 210000004748 cultured cell Anatomy 0.000 description 1
• 125000004122 cyclic group Chemical group 0.000 description 1
• 230000001351 cycling effect Effects 0.000 description 1
• 239000003260 cyclooxygenase 1 inhibitor Substances 0.000 description 1
• 239000003255 cyclooxygenase 2 inhibitor Substances 0.000 description 1
• NXQGGXCHGDYOHB-UHFFFAOYSA-L cyclopenta-1,4-dien-1-yl(diphenyl)phosphane;dichloropalladium;iron(2+) Chemical compound [Fe+2].Cl[Pd]Cl.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1.[CH-]1C=CC(P(C=2C=CC=CC=2)C=2C=CC=CC=2)=C1 NXQGGXCHGDYOHB-UHFFFAOYSA-L 0.000 description 1
• 125000006312 cyclopentyl amino group Chemical group [H]N(*)C1([H])C([H])([H])C([H])([H])C([H])([H])C1([H])[H] 0.000 description 1
• 208000031513 cyst Diseases 0.000 description 1
• 235000018417 cysteine Nutrition 0.000 description 1
• XUJNEKJLAYXESH-UHFFFAOYSA-N cysteine Natural products SCC(N)C(O)=O XUJNEKJLAYXESH-UHFFFAOYSA-N 0.000 description 1
• 108010004073 cysteinylcysteine Proteins 0.000 description 1
• 230000016396 cytokine production Effects 0.000 description 1
• 238000011393 cytotoxic chemotherapy Methods 0.000 description 1
• 230000009849 deactivation Effects 0.000 description 1
• 230000034994 death Effects 0.000 description 1
• 239000003405 delayed action preparation Substances 0.000 description 1
• 238000012217 deletion Methods 0.000 description 1
• 230000037430 deletion Effects 0.000 description 1
• 229960003964 deoxycholic acid Drugs 0.000 description 1
• 238000010511 deprotection reaction Methods 0.000 description 1
• 230000001687 destabilization Effects 0.000 description 1
• 235000019404 dichlorodifluoromethane Nutrition 0.000 description 1
• 229940042935 dichlorodifluoromethane Drugs 0.000 description 1
• 229940087091 dichlorotetrafluoroethane Drugs 0.000 description 1
• 235000014113 dietary fatty acids Nutrition 0.000 description 1
• GGSUCNLOZRCGPQ-UHFFFAOYSA-N diethylaniline Chemical compound CCN(CC)C1=CC=CC=C1 GGSUCNLOZRCGPQ-UHFFFAOYSA-N 0.000 description 1
• 239000013024 dilution buffer Substances 0.000 description 1
• 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 description 1
• 229960001760 dimethyl sulfoxide Drugs 0.000 description 1
• 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 1
• 208000037765 diseases and disorders Diseases 0.000 description 1
• 239000002270 dispersing agent Substances 0.000 description 1
• 238000004821 distillation Methods 0.000 description 1
• PMMYEEVYMWASQN-UHFFFAOYSA-N dl-hydroxyproline Natural products OC1C[NH2+]C(C([O-])=O)C1 PMMYEEVYMWASQN-UHFFFAOYSA-N 0.000 description 1
• 238000007876 drug discovery Methods 0.000 description 1
• 238000001035 drying Methods 0.000 description 1
• 239000000975 dye Substances 0.000 description 1
• 210000000624 ear auricle Anatomy 0.000 description 1
• 230000002526 effect on cardiovascular system Effects 0.000 description 1
• 239000012636 effector Substances 0.000 description 1
• 238000010828 elution Methods 0.000 description 1
• 230000013020 embryo development Effects 0.000 description 1
• 210000002257 embryonic structure Anatomy 0.000 description 1
• 230000001804 emulsifying effect Effects 0.000 description 1
• 230000002124 endocrine Effects 0.000 description 1
• 239000007920 enema Substances 0.000 description 1
• 229940079360 enema for constipation Drugs 0.000 description 1
• 239000002702 enteric coating Substances 0.000 description 1
• 238000009505 enteric coating Methods 0.000 description 1
• 230000002255 enzymatic effect Effects 0.000 description 1
• 238000006911 enzymatic reaction Methods 0.000 description 1
• 230000032050 esterification Effects 0.000 description 1
• 238000005886 esterification reaction Methods 0.000 description 1
• 229960005309 estradiol Drugs 0.000 description 1
• 229930182833 estradiol Natural products 0.000 description 1
• 239000012259 ether extract Substances 0.000 description 1
• DQYBDCGIPTYXML-UHFFFAOYSA-N ethoxyethane;hydrate Chemical compound O.CCOCC DQYBDCGIPTYXML-UHFFFAOYSA-N 0.000 description 1
• LVGKNOAMLMIIKO-QXMHVHEDSA-N ethyl oleate Chemical compound CCCCCCCC\C=C/CCCCCCCC(=O)OCC LVGKNOAMLMIIKO-QXMHVHEDSA-N 0.000 description 1
• 229940093471 ethyl oleate Drugs 0.000 description 1
• 125000000031 ethylamino group Chemical group [H]C([H])([H])C([H])([H])N([H])[*] 0.000 description 1
• 238000011156 evaluation Methods 0.000 description 1
• 230000007717 exclusion Effects 0.000 description 1
• 208000012997 experimental autoimmune encephalomyelitis Diseases 0.000 description 1
• 210000002744 extracellular matrix Anatomy 0.000 description 1
• 239000003889 eye drop Substances 0.000 description 1
• 229940012356 eye drops Drugs 0.000 description 1
• 239000000194 fatty acid Substances 0.000 description 1
• 229930195729 fatty acid Natural products 0.000 description 1
• 150000004665 fatty acids Chemical class 0.000 description 1
• 229950003499 fibrin Drugs 0.000 description 1
• 210000002950 fibroblast Anatomy 0.000 description 1
• 230000003176 fibrotic effect Effects 0.000 description 1
• 239000011888 foil Substances 0.000 description 1
• 239000012634 fragment Substances 0.000 description 1
• 239000012458 free base Substances 0.000 description 1
• VZCYOOQTPOCHFL-OWOJBTEDSA-L fumarate(2-) Chemical class [O-]C(=O)\C=C\C([O-])=O VZCYOOQTPOCHFL-OWOJBTEDSA-L 0.000 description 1
• 125000000524 functional group Chemical group 0.000 description 1
• 238000007306 functionalization reaction Methods 0.000 description 1
• 230000002538 fungal effect Effects 0.000 description 1
• 150000002240 furans Chemical class 0.000 description 1
• 108020001507 fusion proteins Proteins 0.000 description 1
• 102000037865 fusion proteins Human genes 0.000 description 1
• 229960003692 gamma aminobutyric acid Drugs 0.000 description 1
• 239000007789 gas Substances 0.000 description 1
• 239000007903 gelatin capsule Substances 0.000 description 1
• 239000011521 glass Substances 0.000 description 1
• 235000013922 glutamic acid Nutrition 0.000 description 1
• 239000004220 glutamic acid Substances 0.000 description 1
• 125000005456 glyceride group Chemical group 0.000 description 1
• 239000002622 gonadotropin Substances 0.000 description 1
• 229940093915 gynecological organic acid Drugs 0.000 description 1
• 230000009931 harmful effect Effects 0.000 description 1
• 238000003306 harvesting Methods 0.000 description 1
• 201000011066 hemangioma Diseases 0.000 description 1
• 201000005787 hematologic cancer Diseases 0.000 description 1
• 208000024200 hematopoietic and lymphoid system neoplasm Diseases 0.000 description 1
• 208000018706 hematopoietic system disease Diseases 0.000 description 1
• 230000011132 hemopoiesis Effects 0.000 description 1
• 125000004475 heteroaralkyl group Chemical group 0.000 description 1
• 229940088597 hormone Drugs 0.000 description 1
• 239000005556 hormone Substances 0.000 description 1
• 102000055590 human KDR Human genes 0.000 description 1
• 150000004677 hydrates Chemical class 0.000 description 1
• IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 description 1
• 150000003840 hydrochlorides Chemical class 0.000 description 1
• 229920001600 hydrophobic polymer Polymers 0.000 description 1
• 229960002591 hydroxyproline Drugs 0.000 description 1
• 239000001866 hydroxypropyl methyl cellulose Substances 0.000 description 1
• 235000010979 hydroxypropyl methyl cellulose Nutrition 0.000 description 1
• 229920003088 hydroxypropyl methyl cellulose Polymers 0.000 description 1
• 230000000521 hyperimmunizing effect Effects 0.000 description 1
• 206010020718 hyperplasia Diseases 0.000 description 1
• 150000002460 imidazoles Chemical class 0.000 description 1
• 230000002519 immonomodulatory effect Effects 0.000 description 1
• 230000005934 immune activation Effects 0.000 description 1
• 230000001900 immune effect Effects 0.000 description 1
• 230000036737 immune function Effects 0.000 description 1
• 230000028993 immune response Effects 0.000 description 1
• 238000003018 immunoassay Methods 0.000 description 1
• 229960003444 immunosuppressant agent Drugs 0.000 description 1
• 239000003018 immunosuppressive agent Substances 0.000 description 1
• 230000001771 impaired effect Effects 0.000 description 1
• 230000001976 improved effect Effects 0.000 description 1
• 230000006872 improvement Effects 0.000 description 1
• 238000010874 in vitro model Methods 0.000 description 1
• 238000010348 incorporation Methods 0.000 description 1
• PZOUSPYUWWUPPK-UHFFFAOYSA-N indole Natural products CC1=CC=CC2=C1C=CN2 PZOUSPYUWWUPPK-UHFFFAOYSA-N 0.000 description 1
• RKJUIXBNRJVNHR-UHFFFAOYSA-N indolenine Natural products C1=CC=C2CC=NC2=C1 RKJUIXBNRJVNHR-UHFFFAOYSA-N 0.000 description 1
• 230000001939 inductive effect Effects 0.000 description 1
• 210000004969 inflammatory cell Anatomy 0.000 description 1
• 208000027866 inflammatory disease Diseases 0.000 description 1
• 239000004615 ingredient Substances 0.000 description 1
• 230000000968 intestinal effect Effects 0.000 description 1
• 238000010255 intramuscular injection Methods 0.000 description 1
• 239000007927 intramuscular injection Substances 0.000 description 1
• 238000007913 intrathecal administration Methods 0.000 description 1
• 238000001990 intravenous administration Methods 0.000 description 1
• 238000007914 intraventricular administration Methods 0.000 description 1
• 150000002500 ions Chemical class 0.000 description 1
• 230000001788 irregular Effects 0.000 description 1
• 230000000302 ischemic effect Effects 0.000 description 1
• FZWBNHMXJMCXLU-BLAUPYHCSA-N isomaltotriose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1OC[C@@H]1[C@@H](O)[C@H](O)[C@@H](O)[C@@H](OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O)O1 FZWBNHMXJMCXLU-BLAUPYHCSA-N 0.000 description 1
• 150000003854 isothiazoles Chemical class 0.000 description 1
• 210000001117 keloid Anatomy 0.000 description 1
• 230000003902 lesion Effects 0.000 description 1
• 230000002197 limbic effect Effects 0.000 description 1
• 230000000670 limiting effect Effects 0.000 description 1
• DLEDOFVPSDKWEF-UHFFFAOYSA-N lithium butane Chemical compound [Li+].CCC[CH2-] DLEDOFVPSDKWEF-UHFFFAOYSA-N 0.000 description 1
• 239000007937 lozenge Substances 0.000 description 1
• 239000000314 lubricant Substances 0.000 description 1
• 210000005265 lung cell Anatomy 0.000 description 1
• 208000020816 lung neoplasm Diseases 0.000 description 1
• 210000005073 lymphatic endothelial cell Anatomy 0.000 description 1
• 210000001365 lymphatic vessel Anatomy 0.000 description 1
• 239000008176 lyophilized powder Substances 0.000 description 1
• 239000012139 lysis buffer Substances 0.000 description 1
• 229910052943 magnesium sulfate Inorganic materials 0.000 description 1
• 235000019341 magnesium sulphate Nutrition 0.000 description 1
• 230000036210 malignancy Effects 0.000 description 1
• CUONGYYJJVDODC-UHFFFAOYSA-N malononitrile Chemical compound N#CCC#N CUONGYYJJVDODC-UHFFFAOYSA-N 0.000 description 1
• 239000000594 mannitol Substances 0.000 description 1
• 235000010355 mannitol Nutrition 0.000 description 1
• 239000004579 marble Substances 0.000 description 1
• 230000035800 maturation Effects 0.000 description 1
• 230000007246 mechanism Effects 0.000 description 1
• 239000012528 membrane Substances 0.000 description 1
• 230000002503 metabolic effect Effects 0.000 description 1
• 229910052751 metal Inorganic materials 0.000 description 1
• 239000002184 metal Substances 0.000 description 1
• 230000031864 metaphase Effects 0.000 description 1
• AFVFQIVMOAPDHO-UHFFFAOYSA-M methanesulfonate group Chemical class CS(=O)(=O)[O-] AFVFQIVMOAPDHO-UHFFFAOYSA-M 0.000 description 1
• 229920000609 methyl cellulose Polymers 0.000 description 1
• 239000001923 methylcellulose Substances 0.000 description 1
• 229960002900 methylcellulose Drugs 0.000 description 1
• 235000010981 methylcellulose Nutrition 0.000 description 1
• 230000000813 microbial effect Effects 0.000 description 1
• 210000004088 microvessel Anatomy 0.000 description 1
• 238000003801 milling Methods 0.000 description 1
• 230000003278 mimic effect Effects 0.000 description 1
• 239000002480 mineral oil Substances 0.000 description 1
• 150000007522 mineralic acids Chemical class 0.000 description 1
• 230000000116 mitigating effect Effects 0.000 description 1
• 229960004857 mitomycin Drugs 0.000 description 1
• 230000011278 mitosis Effects 0.000 description 1
• 210000000479 mitotic spindle apparatus Anatomy 0.000 description 1
• 238000007799 mixed lymphocyte reaction assay Methods 0.000 description 1
• 238000002156 mixing Methods 0.000 description 1
• 238000012544 monitoring process Methods 0.000 description 1
• HZAXFHJVJLSVMW-UHFFFAOYSA-N monoethanolamine hydrochloride Natural products NCCO HZAXFHJVJLSVMW-UHFFFAOYSA-N 0.000 description 1
• 206010028417 myasthenia gravis Diseases 0.000 description 1
• 210000005012 myelin Anatomy 0.000 description 1
• 230000002107 myocardial effect Effects 0.000 description 1
• MZRVEZGGRBJDDB-UHFFFAOYSA-N n-Butyllithium Substances [Li]CCCC MZRVEZGGRBJDDB-UHFFFAOYSA-N 0.000 description 1
• ILCQYORZHHFLNL-UHFFFAOYSA-N n-bromoaniline Chemical compound BrNC1=CC=CC=C1 ILCQYORZHHFLNL-UHFFFAOYSA-N 0.000 description 1
• AOTOAIFCUZOGTP-UHFFFAOYSA-N n-ethyl-2,3,4-trimethylpentan-3-amine Chemical compound CCNC(C)(C(C)C)C(C)C AOTOAIFCUZOGTP-UHFFFAOYSA-N 0.000 description 1
• 239000006199 nebulizer Substances 0.000 description 1
• 230000027405 negative regulation of phosphorylation Effects 0.000 description 1
• 201000003142 neovascular glaucoma Diseases 0.000 description 1
• 230000001272 neurogenic effect Effects 0.000 description 1
• 230000003472 neutralizing effect Effects 0.000 description 1
• 210000000440 neutrophil Anatomy 0.000 description 1
• 150000002823 nitrates Chemical class 0.000 description 1
• 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 description 1
• 229920001220 nitrocellulos Polymers 0.000 description 1
• 229940127082 non-receptor tyrosine kinase inhibitor Drugs 0.000 description 1
• 229940021182 non-steroidal anti-inflammatory drug Drugs 0.000 description 1
• 231100000956 nontoxicity Toxicity 0.000 description 1
• 238000010899 nucleation Methods 0.000 description 1
• 238000000424 optical density measurement Methods 0.000 description 1
• 150000007524 organic acids Chemical class 0.000 description 1
• 235000005985 organic acids Nutrition 0.000 description 1
• 229920000620 organic polymer Polymers 0.000 description 1
• 239000003791 organic solvent mixture Substances 0.000 description 1
• 230000008520 organization Effects 0.000 description 1
• 229960003104 ornithine Drugs 0.000 description 1
• 210000000963 osteoblast Anatomy 0.000 description 1
• 201000008968 osteosarcoma Diseases 0.000 description 1
• 230000002611 ovarian Effects 0.000 description 1
• 210000001672 ovary Anatomy 0.000 description 1
• 230000002018 overexpression Effects 0.000 description 1
• 210000003101 oviduct Anatomy 0.000 description 1
• ZEERHWXRRLRIQO-UHFFFAOYSA-N oxan-4-yl 4-methylbenzenesulfonate Chemical compound C1=CC(C)=CC=C1S(=O)(=O)OC1CCOCC1 ZEERHWXRRLRIQO-UHFFFAOYSA-N 0.000 description 1
• 239000001301 oxygen Substances 0.000 description 1
• 229910052763 palladium Inorganic materials 0.000 description 1
• PIBWKRNGBLPSSY-UHFFFAOYSA-L palladium(II) chloride Chemical compound Cl[Pd]Cl PIBWKRNGBLPSSY-UHFFFAOYSA-L 0.000 description 1
• 210000000496 pancreas Anatomy 0.000 description 1
• 230000003076 paracrine Effects 0.000 description 1
• 244000052769 pathogen Species 0.000 description 1
• 230000037361 pathway Effects 0.000 description 1
• 229950000964 pepstatin Drugs 0.000 description 1
• 108010091212 pepstatin Proteins 0.000 description 1
• FAXGPCHRFPCXOO-LXTPJMTPSA-N pepstatin A Chemical compound OC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C)NC(=O)C[C@H](O)[C@H](CC(C)C)NC(=O)[C@H](C(C)C)NC(=O)[C@H](C(C)C)NC(=O)CC(C)C FAXGPCHRFPCXOO-LXTPJMTPSA-N 0.000 description 1
• 208000011906 peptic ulcer disease Diseases 0.000 description 1
• 239000000137 peptide hydrolase inhibitor Substances 0.000 description 1
• 210000005259 peripheral blood Anatomy 0.000 description 1
• 239000011886 peripheral blood Substances 0.000 description 1
• 150000002978 peroxides Chemical class 0.000 description 1
• 230000002085 persistent effect Effects 0.000 description 1
• 239000002831 pharmacologic agent Substances 0.000 description 1
• 230000000144 pharmacologic effect Effects 0.000 description 1
• ISWSIDIOOBJBQZ-UHFFFAOYSA-M phenolate Chemical compound [O-]C1=CC=CC=C1 ISWSIDIOOBJBQZ-UHFFFAOYSA-M 0.000 description 1
• 229940031826 phenolate Drugs 0.000 description 1
• 210000004214 philadelphia chromosome Anatomy 0.000 description 1
• 239000010452 phosphate Substances 0.000 description 1
• NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
• 125000002467 phosphate group Chemical group [H]OP(=O)(O[H])O[*] 0.000 description 1
• 239000002935 phosphatidylinositol 3 kinase inhibitor Substances 0.000 description 1
• DCWXELXMIBXGTH-QMMMGPOBSA-N phosphonotyrosine Chemical group OC(=O)[C@@H](N)CC1=CC=C(OP(O)(O)=O)C=C1 DCWXELXMIBXGTH-QMMMGPOBSA-N 0.000 description 1
• LFGREXWGYUGZLY-UHFFFAOYSA-N phosphoryl Chemical group [P]=O LFGREXWGYUGZLY-UHFFFAOYSA-N 0.000 description 1
• 230000035790 physiological processes and functions Effects 0.000 description 1
• 239000000049 pigment Substances 0.000 description 1
• 239000006187 pill Substances 0.000 description 1
• HXEACLLIILLPRG-UHFFFAOYSA-N pipecolic acid Chemical compound OC(=O)C1CCCCN1 HXEACLLIILLPRG-UHFFFAOYSA-N 0.000 description 1
• RFIOZSIHFNEKFF-UHFFFAOYSA-M piperazine-1-carboxylate Chemical compound [O-]C(=O)N1CCNCC1 RFIOZSIHFNEKFF-UHFFFAOYSA-M 0.000 description 1
• 210000002826 placenta Anatomy 0.000 description 1
• 230000028742 placenta development Effects 0.000 description 1
• 239000004014 plasticizer Substances 0.000 description 1
• 238000002264 polyacrylamide gel electrophoresis Methods 0.000 description 1
• 125000003367 polycyclic group Chemical group 0.000 description 1
• 229940068886 polyethylene glycol 300 Drugs 0.000 description 1
• 229920000642 polymer Polymers 0.000 description 1
• 239000000256 polyoxyethylene sorbitan monolaurate Substances 0.000 description 1
• 235000010486 polyoxyethylene sorbitan monolaurate Nutrition 0.000 description 1
• 239000001816 polyoxyethylene sorbitan tristearate Substances 0.000 description 1
• 235000010988 polyoxyethylene sorbitan tristearate Nutrition 0.000 description 1
• 229920001184 polypeptide Polymers 0.000 description 1
• 229920001282 polysaccharide Polymers 0.000 description 1
• 239000005017 polysaccharide Substances 0.000 description 1
• 150000004804 polysaccharides Chemical class 0.000 description 1
• 229940099511 polysorbate 65 Drugs 0.000 description 1
• 230000004481 post-translational protein modification Effects 0.000 description 1
• 239000011591 potassium Substances 0.000 description 1
• 229910052700 potassium Inorganic materials 0.000 description 1
• 229920001592 potato starch Polymers 0.000 description 1
• 229940116317 potato starch Drugs 0.000 description 1
• 239000003755 preservative agent Substances 0.000 description 1
• 230000002335 preservative effect Effects 0.000 description 1
• 230000002265 prevention Effects 0.000 description 1
• 210000004986 primary T-cell Anatomy 0.000 description 1
• 102000004196 processed proteins & peptides Human genes 0.000 description 1
• 230000002035 prolonged effect Effects 0.000 description 1
• 239000003380 propellant Substances 0.000 description 1
• 238000011321 prophylaxis Methods 0.000 description 1
• 210000002307 prostate Anatomy 0.000 description 1
• 201000001514 prostate carcinoma Diseases 0.000 description 1
• 125000006239 protecting group Chemical group 0.000 description 1
• 230000029983 protein stabilization Effects 0.000 description 1
• 230000006337 proteolytic cleavage Effects 0.000 description 1
• 150000003216 pyrazines Chemical class 0.000 description 1
• 150000003217 pyrazoles Chemical class 0.000 description 1
• 150000003230 pyrimidines Chemical class 0.000 description 1
• 150000003233 pyrroles Chemical class 0.000 description 1
• JWVCLYRUEFBMGU-UHFFFAOYSA-N quinazoline Chemical compound N1=CN=CC2=CC=CC=C21 JWVCLYRUEFBMGU-UHFFFAOYSA-N 0.000 description 1
• 150000003246 quinazolines Chemical class 0.000 description 1
• 230000008707 rearrangement Effects 0.000 description 1
• 238000001953 recrystallisation Methods 0.000 description 1
• 210000000664 rectum Anatomy 0.000 description 1
• 230000022983 regulation of cell cycle Effects 0.000 description 1
• 230000006760 regulation of extracellular matrix disassembly Effects 0.000 description 1
• 238000007634 remodeling Methods 0.000 description 1
• 208000017443 reproductive system disease Diseases 0.000 description 1
• 210000001525 retina Anatomy 0.000 description 1
• 238000004007 reversed phase HPLC Methods 0.000 description 1
• 229940100486 rice starch Drugs 0.000 description 1
• 238000011808 rodent model Methods 0.000 description 1
• 239000012723 sample buffer Substances 0.000 description 1
• 238000012216 screening Methods 0.000 description 1
• 150000003346 selenoethers Chemical class 0.000 description 1
• 238000000926 separation method Methods 0.000 description 1
• 230000036303 septic shock Effects 0.000 description 1
• 230000009919 sequestration Effects 0.000 description 1
• 238000013207 serial dilution Methods 0.000 description 1
• 239000008159 sesame oil Substances 0.000 description 1
• 235000011803 sesame oil Nutrition 0.000 description 1
• ZLGIYFNHBLSMPS-ATJNOEHPSA-N shellac Chemical compound OCCCCCC(O)C(O)CCCCCCCC(O)=O.C1C23[C@H](C(O)=O)CCC2[C@](C)(CO)[C@@H]1C(C(O)=O)=C[C@@H]3O ZLGIYFNHBLSMPS-ATJNOEHPSA-N 0.000 description 1
• 239000004208 shellac Substances 0.000 description 1
• 229940113147 shellac Drugs 0.000 description 1
• 235000013874 shellac Nutrition 0.000 description 1
• 239000000377 silicon dioxide Substances 0.000 description 1
• 210000004927 skin cell Anatomy 0.000 description 1
• 239000002002 slurry Substances 0.000 description 1
• 210000002460 smooth muscle Anatomy 0.000 description 1
• 229910052708 sodium Inorganic materials 0.000 description 1
• 235000010413 sodium alginate Nutrition 0.000 description 1
• 239000000661 sodium alginate Substances 0.000 description 1
• 229940005550 sodium alginate Drugs 0.000 description 1
• WRIKHQLVHPKCJU-UHFFFAOYSA-N sodium bis(trimethylsilyl)amide Chemical compound C[Si](C)(C)N([Na])[Si](C)(C)C WRIKHQLVHPKCJU-UHFFFAOYSA-N 0.000 description 1
• 239000012279 sodium borohydride Substances 0.000 description 1
• 229910000033 sodium borohydride Inorganic materials 0.000 description 1
• FHHPUSMSKHSNKW-SMOYURAASA-M sodium deoxycholate Chemical compound [Na+].C([C@H]1CC2)[C@H](O)CC[C@]1(C)[C@@H]1[C@@H]2[C@@H]2CC[C@H]([C@@H](CCC([O-])=O)C)[C@@]2(C)[C@@H](O)C1 FHHPUSMSKHSNKW-SMOYURAASA-M 0.000 description 1
• 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 1
• 239000007901 soft capsule Substances 0.000 description 1
• 239000012439 solid excipient Substances 0.000 description 1
• 239000007790 solid phase Substances 0.000 description 1
• 238000001228 spectrum Methods 0.000 description 1
• 239000007921 spray Substances 0.000 description 1
• 230000006641 stabilisation Effects 0.000 description 1
• 238000011105 stabilization Methods 0.000 description 1
• 230000000087 stabilizing effect Effects 0.000 description 1
• 210000000130 stem cell Anatomy 0.000 description 1
• 150000003431 steroids Chemical class 0.000 description 1
• 210000002784 stomach Anatomy 0.000 description 1
• 201000000498 stomach carcinoma Diseases 0.000 description 1
• 150000003890 succinate salts Chemical class 0.000 description 1
• 239000005720 sucrose Substances 0.000 description 1
• 125000005420 sulfonamido group Chemical group S(=O)(=O)(N*)* 0.000 description 1
• 239000011593 sulfur Substances 0.000 description 1
• 150000003467 sulfuric acid derivatives Chemical class 0.000 description 1
• 239000006228 supernatant Substances 0.000 description 1
• 239000013589 supplement Substances 0.000 description 1
• 239000002511 suppository base Substances 0.000 description 1
• 230000004083 survival effect Effects 0.000 description 1
• 239000000375 suspending agent Substances 0.000 description 1
• 238000003786 synthesis reaction Methods 0.000 description 1
• 230000001839 systemic circulation Effects 0.000 description 1
• 201000000596 systemic lupus erythematosus Diseases 0.000 description 1
• 230000008685 targeting Effects 0.000 description 1
• 235000002906 tartaric acid Nutrition 0.000 description 1
• 150000003892 tartrate salts Chemical class 0.000 description 1
• 230000002123 temporal effect Effects 0.000 description 1
• ROUYFJUVMYHXFJ-UHFFFAOYSA-N tert-butyl 4-oxopiperidine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCC(=O)CC1 ROUYFJUVMYHXFJ-UHFFFAOYSA-N 0.000 description 1
• CWXPZXBSDSIRCS-UHFFFAOYSA-N tert-butyl piperazine-1-carboxylate Chemical compound CC(C)(C)OC(=O)N1CCNCC1 CWXPZXBSDSIRCS-UHFFFAOYSA-N 0.000 description 1
• 150000003536 tetrazoles Chemical class 0.000 description 1
• 238000002560 therapeutic procedure Methods 0.000 description 1
• 229960004072 thrombin Drugs 0.000 description 1
• 229940104230 thymidine Drugs 0.000 description 1
• 230000001646 thyrotropic effect Effects 0.000 description 1
• 239000003104 tissue culture media Substances 0.000 description 1
• 239000004408 titanium dioxide Substances 0.000 description 1
• 238000011200 topical administration Methods 0.000 description 1
• 230000000699 topical effect Effects 0.000 description 1
• 231100000331 toxic Toxicity 0.000 description 1
• 230000002588 toxic effect Effects 0.000 description 1
• 235000010487 tragacanth Nutrition 0.000 description 1
• 239000000196 tragacanth Substances 0.000 description 1
• 229940116362 tragacanth Drugs 0.000 description 1
• FGMPLJWBKKVCDB-UHFFFAOYSA-N trans-L-hydroxy-proline Natural products ON1CCCC1C(O)=O FGMPLJWBKKVCDB-UHFFFAOYSA-N 0.000 description 1
• 238000010361 transduction Methods 0.000 description 1
• 230000026683 transduction Effects 0.000 description 1
• 230000009466 transformation Effects 0.000 description 1
• 230000005945 translocation Effects 0.000 description 1
• 102000027257 transmembrane receptors Human genes 0.000 description 1
• 108091008578 transmembrane receptors Proteins 0.000 description 1
• 150000003626 triacylglycerols Chemical class 0.000 description 1
• 150000003852 triazoles Chemical class 0.000 description 1
• QORWJWZARLRLPR-UHFFFAOYSA-H tricalcium bis(phosphate) Chemical compound [Ca+2].[Ca+2].[Ca+2].[O-]P([O-])([O-])=O.[O-]P([O-])([O-])=O QORWJWZARLRLPR-UHFFFAOYSA-H 0.000 description 1
• 229940029284 trichlorofluoromethane Drugs 0.000 description 1
• 125000000876 trifluoromethoxy group Chemical group FC(F)(F)O* 0.000 description 1
• UFTFJSFQGQCHQW-UHFFFAOYSA-N triformin Chemical compound O=COCC(OC=O)COC=O UFTFJSFQGQCHQW-UHFFFAOYSA-N 0.000 description 1
• NHDIQVFFNDKAQU-UHFFFAOYSA-N tripropan-2-yl borate Chemical compound CC(C)OB(OC(C)C)OC(C)C NHDIQVFFNDKAQU-UHFFFAOYSA-N 0.000 description 1
• IHIXIJGXTJIKRB-UHFFFAOYSA-N trisodium vanadate Chemical compound [Na+].[Na+].[Na+].[O-][V]([O-])([O-])=O IHIXIJGXTJIKRB-UHFFFAOYSA-N 0.000 description 1
• 239000002451 tumor necrosis factor inhibitor Substances 0.000 description 1
• 230000005751 tumor progression Effects 0.000 description 1
• 208000001072 type 2 diabetes mellitus Diseases 0.000 description 1
• 210000003606 umbilical vein Anatomy 0.000 description 1
• 241000701161 unidentified adenovirus Species 0.000 description 1
• 230000003827 upregulation Effects 0.000 description 1
• 210000003932 urinary bladder Anatomy 0.000 description 1
• LSGOVYNHVSXFFJ-UHFFFAOYSA-N vanadate(3-) Chemical compound [O-][V]([O-])([O-])=O LSGOVYNHVSXFFJ-UHFFFAOYSA-N 0.000 description 1
• 239000003981 vehicle Substances 0.000 description 1
• 201000009371 venous hemangioma Diseases 0.000 description 1
• 230000029812 viral genome replication Effects 0.000 description 1
• 238000005303 weighing Methods 0.000 description 1
• 230000004584 weight gain Effects 0.000 description 1
• 235000019786 weight gain Nutrition 0.000 description 1
• 229940100445 wheat starch Drugs 0.000 description 1
• JPZXHKDZASGCLU-LBPRGKRZSA-N β-(2-naphthyl)-alanine Chemical compound C1=CC=CC2=CC(C[C@H](N)C(O)=O)=CC=C21 JPZXHKDZASGCLU-LBPRGKRZSA-N 0.000 description 1